CURRICULUM VITAE Education - findadoc.unchealthcare.org · Cabrera J, Otley A, Rick J, Bousvaros A, Rosh J, Grossman A, Saeed S, Kay M, Carvalho R, Keljo D, Pfefferkorn M, Faubion

Michael D. Kappelman Updated August 2017

1

CURRICULUM VITAE

Education: Sept 2006 - May 2007 Harvard School of Public Health Harvard University, Boston MA Degree: MPH, Clinical Effectiveness July 2005 - June 2007 Harvard Medical School, Boston MA Fellowship in Pediatric Health Services Research July 2004 - June 2007 Harvard Medical School, Boston MA Fellowship in Pediatric Gastroenterology and Nutrition July 2001 – June 2004 Massachusetts General Hospital, Boston MA Internship and Residency in Pediatrics Sept 1996 – May 2001 Washington University School of Medicine, St. Louis, MO Degree: MD Nov 1999 – Oct 2000 Fulbright Scholarship and Rotary International Ambassadorial

Scholarship, Victor Chang Cardiac Research Institute, University of New South Wales, Sydney, Australia

Sept 1992 – May 1996 Brown University, Providence, RI Degree: Sc.B., Psychology Professional Certifications: 2007-present American Board of Pediatrics, Pediatric Gastroenterology 2004-2013 American Board of Pediatrics, Pediatrics Medical Licensure: 2007-present North Carolina Registered Physician 2006 New York Registered Physician (currently inactive) 2003 Massachusetts Registered Physician (currently inactive) Professional Experience -- Employment History: 07/2017 – present Adjunct Professor of Epidemiology University of North Carolina, Chapel Hill NC 04//2017 - present Professor of Pediatrics University of North Carolina, Chapel Hill NC


2

03/2014 – 06/2017 Adjunct Associate Professor of Epidemiology University of North Carolina, Chapel Hill NC 12/2013 - .4/2017 Associate Professor of Pediatrics University of North Carolina, Chapel Hill NC 8/2011 - 11/2013 Assistant Professor of Pediatrics University of North Carolina, Chapel Hill NC 8/2007 - 7/2011 Research Assistant Professor of Pediatrics University of North Carolina, Chapel Hill NC Honors and Awards: 2017 Crohn’s & Colitis Foundation Rosenthal Award for Patient Support and Care 2009 NASPGHAN Clinical Young Investigator Award 2007 Travel scholarship to attend the AGA Academic Skills Workshop 2006 Gastroenterology Research Group Trainee Scholarship, Methodologies in

Healthcare Outcomes 2006 Travel scholarship to attend the Collaborations in IBD fellow conference 2006 Gastroenterology Research Group/American Gastroenterology Association

Fellow Travel Award 2005 ACG Fellows Forum Award Recipient, American College of Gastroenterology 2003 Cambridge-Somerville Pediatric Resident Teaching Award, Harvard Medical

School 1997 Student Research Prize, Washington University School of Medicine Bibliography: Book Chapters: 1. Boruta MK, Grand R, and Kappelman MD. "Natural History of Indeterminate Colitis,"

Pediatric Inflammatory Bowel Disease, 2nd Ed" [Mamula P, Markowitz J, and Baldassano R (eds)], Springer, 2013, pp. 79-86.

2. Colletti RB, Kappelman MD, Crandal WV, and Margolis PA. “Quality Improvement in Inflammatory Bowel Disease,” Pediatric Inflammatory Bowel Disease, 2nd Ed [Mamula P, Markowitz J, and Baldassano R (eds)], Springe, 2013, pp. 547-554.

3. Kappelman MD. “Will IBD Standards Enhance Patient Care?” Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, 2nd Edition [Irving PM, Siegel CA, Rampton DS, and Shanahan, F (eds)], John Wiley and Sons Ltd, 2011: pp 243-246.


3

4. Kappelman MD and Rufo P. “Medical Therapy for Inflammatory Bowel Disease in Children and Adolescents," Pediatric inflammatory bowel disease: perspective and consequences [(Walker-Smith JA, Lebenthal E, Branski D (eds)] Karger, 2009, vol 14, pp 158–171.

5. Kappelman MD, Grand RJ. "Natural History of Pediatric Indeterminate Colitis,” Pediatric Inflammatory Bowel Disease" [Mamula P, Markowitz J, and Baldassano R (eds)] Springer, 2008:83-90.

Refereed papers/articles: Original Research: 1. Rosen MJ, Karns R, Vallance JE, Bezold R, Waddell A, Collins MH, Haberman Y, Minar P,

Baldassano RN, Hyams JS, Baker SS, Kellermayer R, Noe JD, Griffiths AM, Rosh JR, Crandall WV, Heyman MB, Mack DR, Kappelman MD, Markowitz J, Moulton DE, Leleiko NS, Walters TD, Kugathasan S, Wilson KT, Hogan SP, Denson LA. Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients. Gastroenterology 2017;152:1345-1357 e7.

2. Kugathasan S, Denson LA, Walters TD, Kim MO, Marigorta UM, Schirmer M, Mondal K, Liu C, Griffiths A, Noe JD, Crandall WV, Snapper S, Rabizadeh S, Rosh JR, Shapiro JM, Guthery S, Mack DR, Kellermayer R, Kappelman MD, Steiner S, Moulton DE, Keljo D, Cohen S, Oliva-Hemker M, Heyman MB, Otley AR, Baker SS, Evans JS, Kirschner BS, Patel AS, Ziring D, Trapnell BC, Sylvester FA, Stephens MC, Baldassano RN, Markowitz JF, Cho J, Xavier RJ, Huttenhower C, Aronow BJ, Gibson G, Hyams JS, Dubinsky MC. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet 2017;389:1710-1718.

3. Dotson JL, Cho M, Bricker J, Kappelman MD, Chisolm DJ, Tomer G, Crandall WV, ImproveCareNow Pediatric IBDLHS. Race Differences in Initial Presentation, Early Treatment, and 1-year Outcomes of Pediatric Crohn's Disease: Results from the ImproveCareNow Network. Inflamm Bowel Dis 2017

4. Dotson JL, Cho M, Bricker J, Kappelman MD, Chisolm DJ, Tomer G, Crandall WV,

ImproveCareNow Pediatric IBDLHS. Race Differences in Initial Presentation, Early Treatment, and 1-year Outcomes of Pediatric Crohn's Disease: Results from the ImproveCareNow Network. Inflamm Bowel Dis 2017;23:767-774.

5. Brant SR, Okou DT, Simpson CL, Cutler DJ, Haritunians T, Bradfield JP, Chopra P, Prince

J, Begum F, Kumar A, Huang C, Venkateswaran S, Datta LW, Wei Z, Thomas K, Herrinton LJ, Klapproth JA, Quiros AJ, Seminerio J, Liu Z, Alexander JS, Baldassano RN, Dudley-Brown S, Cross RK, Dassopoulos T, Denson LA, Dhere TA, Dryden GW, Hanson JS, Hou JK, Hussain SZ, Hyams JS, Isaacs KL, Kader H, Kappelman MD, Katz J, Kellermayer R, Kirschner BS, Kuemmerle JF, Kwon JH, Lazarev M, Li E, Mack D, Mannon P, Moulton DE, Newberry RD, Osuntokun BO, Patel AS, Saeed SA, Targan SR, Valentine JF, Wang MH, Zonca M, Rioux JD, Duerr RH, Silverberg MS, Cho JH, Hakonarson H, Zwick ME,


4

McGovern DP, Kugathasan S. Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology 2017;152:206-217 e2.

6. Barnes EL, Kochar B, Long MD, Kappelman MD, Martin CF, Korzenik JR, Crockett SD. Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database. Inflamm Bowel Dis 2017;23:875-881.

7. Barnes EL, Herfarth HH, Sandler RS, Chen W, Jaeger E, Nguyen VM, Robb AR,

Kappelman MD, Martin CF, Long MD. Pouch-Related Symptoms and Quality of Life in Patients with Ileal Pouch-Anal Anastomosis. Inflamm Bowel Dis 2017;23:1218-1224.

8. Abdalla MI, Sandler RS, Kappelman MD, Martin CF, Chen W, Anton K, Long MD.

Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners. Inflamm Bowel Dis 2017;23:325-331.

9. Abdalla MI, Sandler RS, Kappelman MD, Martin CF, Chen W, Anton K, Long MD. The

Impact of Ostomy on Quality of Life and Functional Status of Crohn's Disease Patients. Inflamm Bowel Dis 2016;22:2658-2664.

10. Weaver KN, Kappelman MD, Sandler RS, Martin CF, Chen W, Anton K, Long MD.

Variation in Care of Inflammatory Bowel Diseases Patients in Crohn's and Colitis Foundation of America Partners: Role of Gastroenterologist Practice Setting in Disease Outcomes and Quality Process Measures. Inflamm Bowel Dis 2016;22:2672-2677

11. Kochar B, Aldridge M, Cook SF, Bright R, Mallette M, Moniz H, Shah SA, LeLeiko NS,

Shapiro J, Sands BE, Chen W, Jaeger E, Galanko J, Long MD, Martin CF, Sandler RS, Kappelman MD. Achieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease. J Med Internet Res 2016;18:e124.

12. Gaines LS, Kappelman MD, Long MD. Reply to Dai et al. Am J Gastroenterol

2016;111:1207-8. 13. Gaines LS, Slaughter JC, Horst SN, Schwartz DA, Beaulieu DB, Haman KL, Wang L,

Martin CF, Long MD, Sandler RS, Kappelman MD. Association Between Affective-Cognitive Symptoms of Depression and Exacerbation of Crohn's Disease. Am J Gastroenterol 2016 Jun;111(6):864-70.

14. Chung AE, Sandler RS, Long MD, Ahrens S, Burris JL, Martin CF, Anton K, Robb A,

Caruso TP, Jaeger EL, Chen W, Clark M, Myers K, Dobes A, Kappelman MD. Harnessing person-generated health data to accelerate patient-centered outcomes research: the Crohn's and Colitis Foundation of America PCORnet Patient Powered Research Network (CCFA Partners). J Am Med Inform Assoc 2016 May;23(3):485-90.


5

15. Arvanitis M, DeWalt DA, Martin CF, Long MD, Chen W, Jaeger B, Sandler RS, Kappelman MD. Patient-Reported Outcomes Measurement Information System in Children with Crohn's Disease. J Pediatr 2016 Jul; 174:153-159.e2

16. Geisz M, Ha C, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS, Long MD. Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016 Jun;22(6):1435-41.

17. Singh S, Heien HC, Sangaralingham LR, Schilz SR, Kappelman MD, Shah ND, Loftus EV, Jr. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients with Crohn's Disease. Clin Gastroenterol Hepatol 2016 Aug;14(8):1120-1129.e6.

18. Singh S, Heien HC, Sangaralingham LR, Schilz SR, Kappelman MD, Shah ND, Loftus EV. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis. Aliment Pharmacol Ther 2016;43:994-1003.

19. Randell RL, Gulati AS, Cook SF, Martin CF, Chen W, Jaeger EL, Schoenborn AA, Basta PV, Dejong H, Luo J, Gallant M, Sandler RS, Long MD, Kappelman MD. Collecting Biospecimens From an Internet-Based Prospective Cohort Study of Inflammatory Bowel Disease (CCFA Partners): A Feasibility Study. JMIR Res Protoc 2016;5:e3.

20. Long MD, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS. Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease. J Clin Gastroenterol 2016;50:152-6.

21. Long MD, Weaver K, Kappelman MD, Herfarth HH, Pipkin CA. Photosensitivity to Ultraviolet Light in Patients with Inflammatory Bowel Disease Newly Initiating Immunosuppressive Therapy. Inflamm Bowel Dis 2016;22:E2-3.

22. Brotherton CS, Martin CA, Long MD, Kappelman MD, Sandler RS. Avoidance of Fiber Is

Associated With Greater Risk of Crohn's Disease Flare in a 6-Month Period. Clin Gastroenterol Hepatol 2016 Aug;14(8):1130-6.

23. Cai M, Kappelman MD, Girman CJ, Jain N, Sturmer T, Brookhart MA. Trends and Determinants of Oral Anti-Diabetic Initiation in Youth with Suspected Type 2 Diabetes. PloS one. 2015;10(10):e0140611.

24. Oliva-Hemker M, Hutfless S, Al Kazzi ES, Lerer T, Mack D, LeLeiko N, Griffiths A, Cabrera J, Otley A, Rick J, Bousvaros A, Rosh J, Grossman A, Saeed S, Kay M, Carvalho R, Keljo D, Pfefferkorn M, Faubion W, Jr., Kappelman M, Sudel B, Schaefer ME, Markowitz J, Hyams JS. Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort. J Pediatr 2015; 167:527-32 e1-3.

25. Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates from a National Administrative Database. J Pediatr Gastroenterol Nutr 2016; 62:36-42.


6

26. Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S, Chopra P, Alexander JS, Baldassano RN, Cross RK, Dassopoulos T, Dhere TA, Duerr RH, Hanson JS, Hou JK, Hussain SZ, Isaacs KL, Kachelries KE, Kader H, Kappelman MD, Katz J, Kellermayer R, Kirschner BS, Kuemmerle JF, Kumar A, Kwon JH, Lazarev M, Mannon P, Moulton DE, Osuntokun BO, Patel A, Rioux JD, Rotter JI, Saeed S, Scherl EJ, Silverberg MS, Silverman A, Targan SR, Valentine JF, Wang MH, Simpson CL, Bridges SL, Kimberly RP, Rich SS, Cho JH, Di Rienzo A, Kao LW, McGovern DP, Brant SR, Kugathasan S. Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans. Gastroenterology 2015; 149:1575-86.

27. Dotson JL, Bricker JB, Kappelman MD, Chisolm D, Crandall WV. Assessment of Sex Differences for Treatment, Procedures, Complications, and Associated Conditions Among Adolescents Hospitalized with Crohn's Disease. Inflamm Bowel Dis 2015; 21:2619-24.

28. Cutler DJ, Zwick ME, Okou DT, Prahalad S, Walters T, Guthery SL, Dubinsky M, Baldassano R, Crandall WV, Rosh J, Markowitz J, Stephens M, Kellermayer R, Pfefferkorn M, Heyman MB, LeLeiko N, Mack D, Moulton D, Kappelman MD, Kumar A, Prince J, Bose P, Mondal K, Ramachandran D, Bohnsack JF, Griffiths AM, Haberman Y, Essers J, Thompson SD, Aronow B, Keljo DJ, Hyams JS, Denson LA, Kugathasan S. Dissecting Allele Architecture of Early Onset IBD Using High-Density Genotyping. PLoS One 2015;10: e0128074.

29. Grossi V, Lerer T, Griffiths A, LeLeiko N, Cabrera J, Otley A, Rick J, Mack D, Bousvaros A, Rosh J, Grossman A, Saeed S, Kay M, Boyle B, Oliva-Hemker M, Keljo D, Pfefferkorn M, Faubion W, Kappelman MD, Sudel B, Markowitz J, and Hyams JS. Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children with Crohn's Disease. Clin Gastroenterol Hepatol. 2015. doi: 10.1016/j.cgh.2015.04.010.

30. Jensen ET, Cook SF, Allen JK, Logie J, Brookhart MA, Kappelman MD, and Dellon ES. Enrollment factors and bias of disease prevalence estimates in administrative claims data. Annals of epidemiology. 2015. doi: 10.1016/j.annepidem.2015.03.008.

31. Dotson JL, Kappelman MD, Chisolm DJ, Crandall WV. Racial disparities in readmission, complications, and procedures in children with Crohn's disease. Inflamm Bowel Dis. 2015;21(4):801-8.

32. Long MD, Cadigan RJ, Cook SF, Haldeman K, Kuczynski K, Sandler RS, Martin CF, Chen W, and Kappelman MD. Perceptions of patients with inflammatory bowel diseases on biobanking. Inflamm Bowel Dis. 2015;21(1):132-8.

33. Jones PD, Kappelman MD, Martin CF, Chen W, Sandler RS, and Long MD. Exercise decreases risk of future active disease in patients with inflammatory bowel disease in remission. Inflamm Bowel Dis. 2015;21(5):1063-71.

34. Andersen A B, Erichsen R., Kappelman MD, Froslev T, and Ehrenstein V. Parental celiac disease and risk of asthma in offspring: A Danish nationwide cohort study. Clin Epidemiol 2015, 7, 37-44.


7

35. Dotson JL, Crandall WV, Zhang P, Forrest CB, Bailey LC, Colletti RB, et al. Feasibility and validity of the pediatric ulcerative colitis activity index in routine clinical practice. J Pediatr Gastroenterol Nutr. 2015;60(2):200-4.

36. Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health-Care Utilization, Costs, and the Burden of Disease Related to Eosinophilic Esophagitis in the United States. Am J Gastroenterol. 2014 Sep 30. doi: 10.1038/ajg.2014.316

37. Boyle BM., Kappelman MD, Colletti RB, Baldassano RN, Milov DE and Crandall RV. Routine use of thiopurines in maintaining remission in pediatric Crohn's disease. World J Gastroenterol 2014; 20(27): 9185-9190.

38. Buckley J.P, Cook SF, Allen JK, and Kappelman MD. Prevalence of Chronic Narcotic Use Among Children with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol; 2014 (epub ahead of press).

39. Sunseri W, Hyams JS, Lerer T, Mack DR, Griffiths AM, Otley AR, Rosh JR, Carvalho R, Grossman AB, Cabrera J, Pfefferkorn MD, Rick J, Leleiko NS, Hitch MC, Oliva-Hemker M, Saeed A, Kappelman M, Markowitz J, Keljo DJ and Pediatric Inflammatory Bowel Disease Collaborative Research Group Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn's disease. Inflamm Bowel Dis 2014; 20(8): 1341-1345.

40. Dellon ES, Jensen ET, Martin CF, Shaheen NJ, Kappelman MD. Prevalence of eosinophilic esophagitis in the United States. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2014; 12:589-96 e1.

41. Kappelman MD, Farkas DK, Long MD, Erichsen R, Sandler RS, Sorensen HT, Baron JA: Risk of Cancer in Patients with Inflammatory Bowel Diseases: A Nationwide Population-Based Cohort Study with 30 Years of Follow Up Evaluation. Clin Gastroenterol Hepatol Clin Gastroenterol Hepatol 2014; 12:265-73 e1.PubMed PMID: 23602821.

42. Long MD, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS. Risk factors for depression in the elderly inflammatory bowel disease population. J Crohns Colitis. 2014; 8:113-9.

43. Herfarth HH, Martin CF, Sandler RS, Kappelman MD, Long MD. Prevalence of a Gluten-free Diet and Improvement of Clinical Symptoms in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2014; 20:1194-7.

44. Goyal A, Hyams JS, Lerer T, Leleiko NS, Otley AR, Griffiths AM, Rosh JR, Cabrera JM, Oliva-Hemker MM, Mack DR, Rick JN, Pfefferkorn MD, Carvalho R, Grossman AB, Hitch MC, Sudel B, Kappelman MD, Saeed SA, Faubion WA, Schaefer ME, Markowitz JF, Keljo DJ. Liver Enzyme Elevations within Three Months of Diagnosis of Inflammatory Bowel Disease and Likelihood of Liver Disease. J Pediatr Gastroenterol Nutr 2014; 59(3): 321-323.

45. Forrest CB, Crandall W, Bailey C, Zhang P, Joffe M, Colletti RB, Adler J, Baron HI., Berman J, Del Rosario F, Grossman AB, Hoffenberg J, Israel EJ, Kim SC, Lightdale JR, Margolis PA, Marsolo, K, Mehta, DI, Milov DE, Patel AS, Tung J, Kappelman, MD. Effectiveness of Anti-TNFalpha for Crohn Disease: Research in a Pediatric Learning Health System. Pediatrics 2014; 134(1): 37-44.


8

46. Crockett SD, Schectman R, Sturmer T, Kappelman MD. Topiramate Use Does Not Reduce Flares of Inflammatory Bowel Disease. Digestive Diseases and Sciences 2014; 59(7): 1535-1543.

47. Wasan SK, Calderwood AH, Long MD, Kappelman MD, Sandler RS, and Farraye FA. Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. Inflamm Bowel Dis 2014; 20:246-50.

48. Randell RL, Long MD, Cook SF, Wrennall CE, Chen W, MartinCF, Anton K, Sandler RS, Kappelman MD. Validation of an internet-based cohort of inflammatory bowel disease (CCFA partners). Inflamm Bowel Dis 2014; 20:541-4.

49. Lee GJ, Dotson JL, Kappelman MD, King E, Pratt JM, Colletti RB, Bistrick S, Burkam JL, Crandall, WV. Seasonality and Pediatric Inflammatory Bowel Disease: A Multicenter Experience. J Pediatr Gastroenterol Nutr 2014 Jul;59(1):25-8.

50. Hoffenberg EJ, Park KT, Dykes DM, Fridge J, Kappelman MD, Leibowitz I., Tsou M, Colletti RB. Appropriateness of Emergency Department Use in Pediatric Inflammatory Bowel Disease: A Quality Improvement Opportunity. J Pediatr Gastroenterol Nutr 2014; 59(3): 324-326.

51. Lund JL, Cook SF, Allen JK, Carroll CF, Kappelman MD. Patterns of 6-mercaptopurine and azathioprine maintenance therapy among a cohort of commercially insured individuals diagnosed with Crohn's disease in the United States. Clin Epidemiol 2013; 5:501-12.

52. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37:420-9.

53. Kappelman MD, Long MD, Martin C, Dewalt DA, Kinneer PM, Chen W, Lewis J D, Sandler, RS. Evaluation of the Patient-Reported Outcomes Measurement Information System in a Large Cohort of Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2013; 12(8): 1315-1323 e1312.

54. Buckley JP, Kappelman MD, Allen JK, Van Meter SA, Cook SF. The burden of comedication among patients with inflammatory bowel disease. Inflammatory bowel diseases 2013; 19:2725-36.

55. Randell RL, Long MD, Martin CF, Sandler RS, Chen W, Anton K, Kappelman MD: Patient Perception of Chronic Illness Care in a Large Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis 2013; 19:1428-33.

56. Palmer LB, Kappelman MD, Sandler RS, Hayashi PH: Surveillance for Hepatocellular Carcinoma in a Medicaid Cirrhotic Population. J Clin Gastroenterol 2013; 47:713-8. PubMed PMID: 23442840.

57. Long MD, Farraye FA, Okafor PN, Martin C, Sandler RS, Kappelman MD: Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:1018-24.

58. Jensen ET, Kappelman MD, Kim HP, Ringel-Kulka T, Dellon ES: Early Life Exposures as Risk Factors for pediatric Eosinophilic Esophagitis: A Pilot and Feasibility Study. J Pediatr Gastroenterol Nutr 2013; 57:67-71.PubMed PMID: 23518485.


9

59. Ananthakrishnan AN, Long MD, Martin CF, Sandler RS, Kappelman MD: Sleep Disturbance and Risk of Active Disease in Patients with Crohn's Disease and Ulcerative Colitis. Clin Gastroenterol Hepatol 2013; 11:965-71.

60. Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, Brown C, Tung J, Khan K, Faubion W, Jr., Park R, Heikenen J, Yaffee M, Rivera-Bennett MT, Wiedkamp M, Stephens M, Noel R, Nugent M, Nebel J, Simpson P, Kappelman MD, Kugathasan S: Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. Inflamm Bowel Dis 2013; 19:1218-23.

61. Long MD, Martin C, Sandler RS, and Kappelman MD. Increased Risk of Pneumonia Among Patients with Inflammatory Bowel Disease. Am J Gastroenterol, 2013, 108:240-8.

62. Kappelman MD, Moore KR, Allen JK, and Cook SF. Recent trends in the Prevalence of Crohn's Disease and Ulcerative Colitis in a Commercially Insured US Population. Dig Dis Sci. 2013; 58:519-25.

63. Cohen AB, Lee D, Long MD, Kappelman MD, Martin CF, Sandler RS, Lewis JD: Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig Dis Sci 2013; 58:1322-8.

64. Zeisler B, Lerer T, Markowitz J, Mack D, Griffiths A, Bousvaros A, Keljo D, Rosh J, Evans J, Kappelman M, Otley A, Kay M, Grossman A, Saeed S, Carvalho R, Oliva-Hemker M, Faubion W, Sudel B, Pfefferkorn M, Ashai-Khan F, Leleiko N, and Hyams J. Pediatric Inflammatory Bowel Disease Collaborative Research Group. Outcome Following Aminosalicylate Therapy in Children Newly Diagnosed with Ulcerative Colitis: A Prospective Multi-Center Registry Experience. J Pediatr Gastroenterol Nutr. 2013; 56:12-8.

65. Benchimol EI, Cook SF, Erichsen R, Long MD, Bernstein CN, Wong J, Carroll CF, Froslev T, Sampson T, Kappelman MD: International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohns Colitis 2012; S1873-9946(12):402-3.

66. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, Dibonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, and Shaheen NJ. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-87.

67. Lee GJ, Kappelman MD, Boyle B, Colletti RB, King E, Pratt JM, and Crandall WV. Role of sex in the treatment and clinical outcomes of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2012; 55: 701-706.

68. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, and Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143: 390-9.

69. Karve S, Candrilli S, Kappelman MD, Tolleson-Rinehart S, Tennis P, and Andrews E. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease. J Pediatr 2012; 161: 662-70.

70. Crandall WV, Margolis PA, Kappelman MD, King EC, Pratt JM, Boyle BM, Duffy LF, Grunow JE, Kim SC, Leibowitz I, Schoen BT, and Colletti RB. Improved Outcomes in a


10

Quality Improvement Collaborative for Pediatric Inflammatory Bowel Disease. Pediatrics 2012; 129: e1030-41.

71. Long MD, Kappelman MD, Martin CF, Lewis JD, Mayer L, Kinneer PM, and Sandler RS. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis. 2012; 18: 2099-106.

72. Dorn SD, Wei D, Farley JF, Shah ND, Shaheen NJ, Sandler RS, and Kappelman MD. Impact of the 2008-2009 economic recession on screening colonoscopy utilization among the insured. Clin Gastroenterol Hepatol 2012; 10: 278-84.

73. Kappelman MD, Galanko JA, Porter CQ, and Sandler RS. Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child 2011; 96: 1042-46.

74. Crockett SD, Hansen RA, Sturmer T, Schectman R, Darter J, Sandler RS, and Kappelman MD. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis 2011; 18: 1048-56.

75. Kappelman MD, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, Baron JA, and Sorensen HT. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011; 60: 937-43.

76. Hyams J, Lerer T, Mack D, Bousvaros A, Griffiths A, Rosh J, Otley A, Evans J, Stephens M, Kay M, Keljo D, Pfefferkorn M, Saeed S, Crandall W, Michail S, Kappelman MD, Grossman A, Samson C, Sudel B, Oliva-Hemker M, LeLeiko N, Markowitz J. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol 2011; 106(5):981-7.

77. Long MD and Kappelman MD. Reply. Clin Gastroenterology Hepatol. 2011; 9:450-1. 78. Crockett SD and Kappelman MD. Response to thakrar. Am J Gastroenterol 2011; 106:1002-

3. 79. Kappelman MD, Crandall WV, Colletti RB, Goudie A, Leibowitz IH, Duffy L, Milov DE,

Kim SC, Schoen BT, Patel AS, Grunow J, Larry E, Fairbrother G, and Margolis P. Short pediatric Crohn's disease activity index for quality improvement and observational research. Inflamm Bowel Dis. 2011; 17: 112-7.

80. Kappelman MD, Galanko JA, Porter CQ, and Sandler RS. The Risk of Diagnosed Fractures in Children with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2011; 17:1125-30.

81. Long MD, Crandall WV, Leibowitz IH, Duffy L, del Rosario F, Kim SC, Integlia MJ, Berman J, Grunow J, Colletti RB, Schoen BT, Patel AS, Baron H, Israel E, Russell G, Ali S, Herfarth HH, Martin C, and Kappelman MD. ImproveCareNow Collaborative for Pediatric IBD. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 2162-68.

82. Kappelman MD, Porter CQ, Galanko JA, Rifas-Shiman SL, Ollendorf DA, Sandler RS, and Finkelstein JA. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 62-8.

83. Lund JL, Sturmer T, Porter CQ, Sandler RS, and Kappelman MD. Thiazolidinedione use and ulcerative colitis-related flares: An exploratory analysis of administrative data. Inflamm Bowel Dis 201; 17: 787-94.


11

84. Crockett SD, Porter CQ, Martin CF, Sandler RS, and Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol 2010; 105: 1986-930.

85. Schaefer ME, Machan JT, Kawatu D, Langton CR, Markowitz J, Crandall W, Mack DR, Evans JS, Pfefferkorn MD, Griffiths AM, Otley AR, Bousvaros A, Kugathasan S, Rosh JR, Keljo DJ, Carvalho RS, Tomer G, Mamula P, Kay MH, Kerzner B, Oliva-Hemker M, Kappelman MD, Saeed SA, Hyams JS, and Leleiko NS. Factors that determine risk for surgery in pediatric patients with Crohn's disease. Clin Gastroenterol Hepatol 2010; 8: 789-94.

86. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, and Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268-74.

87. Long MD, Porter CQ, Sandler RS, and Kappelman MD. Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7: 549-53.

88. Palmer L, Herfarth H, Porter CQ, Fordham LA, Sandler RS, and Kappelman MD. Diagnostic Ionizing Radiation Exposure in a Population-Based Sample of Children with Inflammatory Bowel Diseases. Am J Gastroenterol 2009; 104: 2816-23.

89. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, and Finkelstein JA. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135:1907-13.

90. Kappelman MD, Bousvaros A, Hyams J, Markowitz J, Pfefferkorn M, Kugathasan S, Rosh J, Otley A, Mack D, Griffiths A, Evans J, Grand R, Langton C, Kleinman K, and Finkelstein JA. Intercenter variation in initial management of children with Crohn's disease. Inflamm Bowel Dis 2007; 13: 890-95.

91. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, and Finkelstein JA. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5:1424-29.

Other Peer Reviewed Articles: 1. Barnes EL, Kappelman MD. Do Shared Exposures Link the Lungs and Gut? Association

Between Asthma and Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2017. 2. Herfarth HH, Long MD, Kappelman MD. Immunosuppression for management of Crohn's

disease. Lancet 2016; 387:747-8. 3. Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of Methotrexate in the Treatment

of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2016; 22:224-33 4. Dotson JL, Kappelman MD. Overuse of the Emergency Department and CT Scans in

Pediatric IBD: Time for Hot Spotting? J Pediatr Gastroenterol Nutr 2015; 61:267-8. 5. Park KT, Crandall WV, Fridge J, Leibowitz IH, Tsou M, Dykes DM, Hoffenberg EJ,

Kappelman MD, Colletti, RB. Implementable strategies and exploratory considerations to


12

reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis 2014; 20:946-51.

6. Long MD, Hutfless S, Kappelman MD, Khalili H, Kaplan GG, Bernstein CN, Colombel JF, Gower-Rousseau C, Herrinton L, Velayos F, Loftus EV, Nguyen GC, Ananthakrishnan AN, Sonnenberg A, Chan A, Sandler RS, Atreja A, Shah SA, Rothman KJ, Leleiko NS, Bright R, Boffetta P, Myers KD, Sands BE. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis 2014; 20:398-415.

7. Melmed GY, Siegel CA, Spiegel BM, Allen JI, Cima R, Colombel JF, Dassopoulos T, Denson LA, Dudley-Brown S, Garb A, Hanauer SB, Kappelman MD, Lewis JD, Lynch I, Moynihan A, Rubin DT, Sartor RB, Schwartz RM, Wolf DC, Ullman TA: Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013; 19:662-8.

8. Kappelman MD: Environmental factors and inflammatory bowel disease: elusive or nonexistent? Inflamm Bowel Dis. 2013; 19:548-9.

9. Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, Pizarro TT, de Zoeten EF, Stappenbeck TS, Plevy SE, Abraham C, Nusrat A, Jobin C, McCole DF, Siegel CA, Higgins PD, Herfarth HH, Hyams J, Sandborn WJ, Loftus EV, Jr., Kappelman MD, Lewis JD, Parkos CA, Sartor RB. Challenges workgroup. Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis. 2013; 19:677-82.

10. Kappelman MD, Dorn SD, Peterson E, Runge T, and Allen JI. Quality of care for gastrointestinal conditions: a primer for gastroenterologists. Am J Gastroenterol. 2011; 106: 1182-87.

11. Crandall WV, Boyle BM, Colletti RB, Margolis PA, and Kappelman MD. Development of process and outcome measures for improvement: lessons learned in a quality improvement collaborative for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17: 2184-91.

12. Crandall W, Kappelman MD, Colletti RB, Leibowitz I, Grunow JE, Ali S, Baron HI, Berman JH, Boyle B, Cohen S, del Rosario F, Denson LA, Duffy L, Integlia MJ, Kim SC, Milov D, Patel AS, Schoen BT, Walkiewicz D, and Margolis P. ImproveCareNow: The development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis. 2011; 17: 450-57.

13. Long MD, Kappelman MD, and Pipkin CA. Nonmelanoma skin cancer in inflammatory bowel disease: A review. Inflamm Bowel Dis. 2011; 17: 1423-27.

14. Kappelman MD and Kim SC. Quality Improvement: An Escape from the Ordinary. AAP Quality Connections. Issue 4, Winter 2010, pg 2.

15. Kappelman MD. Is isotretinoin a causative factor in IBD? Gastroenterology and Hepatology. 2010; 6 (3): 167-169.

16. Kappelman MD, Palmer L, Boyle BM, and Rubin DT. Quality of care in inflammatory bowel disease: A review and discussion. Inflamm Bowel Dis 2010; 16:125-33.


13

17. Crockett SD, Gulati A, Sandler RS, and Kappelman MD. A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol 2009; 104: 2387-93.

18. Boyle BM, Palmer L, and Kappelman MD. Quality of health care in the United States: implications for pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009; 49:272-82.

19. Kappelman MD, Grand RJ. Does inflammatory bowel disease develop in infants? Inflamm Bowel Dis 2008; 14: S6-S8.

20. Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res 2008; 52:867-74.

21. Kappelman MD and Bousvaros A. Probiotic Therapies: The Crossroads of Traditional and Alternative Medicine. Practical Gastroenterolgy. 2005; 29(4):20-36.

22. Hossain T, Kappelman MD, Perez-Atayde AR, Young GJ, Huttner KM, Christou H. Primary ciliary dyskinesia as a cause of neonatal respiratory distress: implications for the neonatologist. J Perinatol. 2003;23(8):684-7.

Manuscripts in press 1. Barnes EL, Kochar BK, Long MD, Martin CF, Kappelman MD. Minority Pediatric Patients

with Inflammatory Bowel Disease Demonstrate an Increased Length of Stay. Inflammatory Bowel Diseases. 2017; accepted, in press. 25 pages.

2. Kochar B, Martin CF, Kappelman MD, Spiegel BM, Chen W, Sandler RS, and Long, MD. Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI PROMIS) Symptom Scales in Subjects with Inflammatory Bowel Diseases. Am J. Gastroenterol; accepted, in press.

3. Chung AE, Vu M, Burris J, Myers K, and Kappelman MD. Crohn's and Colitis Foundation of America Partners Patient-Powered Research Network: Patient Perspectives on Facilitators and Barriers to Building an Impactful Patient-Powered Research Network. Medical Care; accepted, in press

4. Kinlaw, A, Sturmer T, Lund J, Pedersen L, Kappelman M, Daniels J, Forslev T, Mack C, and

Sorensen H. Trends in Antibiotic Use by Birth Season and Birth Year. Pediatrics; accepted, in press

Published abstracts: Markowitz J, Lerer T, Morganstern J, Deslandres C, Tomer G, Schaefer M, Kugathasan S, Faubion W, Kappelman M, Sudel B, Hitch M, Keljo D, Grossman A, Carvalho R, Leleiko N, Saeed S, Oliva-Hemker M, Kay M, Rosh J, Pfefferkorn M, Otley A, Rick J, Mack D, Cabrera J, Griffiths A, Hyams J. Real world outcomes of contemporary treatments in children with Crohn's disease: observations from the pediatric IBD collaborative research group registry. Journal of Crohns & Colitis 2014;8: S400-S400.


14

Arvanitis M, DeWalt DA, Martin CF, Long MD, Chen W, Jaeger EL, Goble L, Sandler RS, and Kappelman MD. Use of the Patient Reported Outcomes Measurement Information System (PROMIS) in a Pediatric Cohort with Inflammatory Bowel Disease (IBD). Gastroenterology. 2014; 146(5): S-26. Dotson JL, Kappelman M, Chisolm D, Crandall W. Healthcare Disparities in Hospitalized Children and Adolescents with Crohn's Disease: Is Race Associated with Differences in Complications or Procedures? Gastroenterology. 2014; 146(5): S-157. Gaines LS, Horst SN, Slaughter JC, Shelton R, Haman K, Wang L, Martin CF, Kappelman M, Long MD, Sandler RS, Beaulieu B, and Schwartz DA... An Internet-Based Cohort Study of the Association Between Depression and Exacerbation of Crohn's Disease. Gastroenterology. 2014; 146(5):S-177. Grossi V, Lerer T, Leleiko NS, Mack DR, Griffiths AM, Otley AR, Pfefferkorn MD, Rosh JR, Oliva-Hemker MO, Saeed SA, Grossman AB, Keljo DJ, Sudel B, Kappelman M, Faubion W, Schaefer M, Tomer G, Deslandres C, Cabrera J, Carvalho R, Hitch M, Morganstern J, Kay MH, Risk J, Markowitz J, and Hyams JS... Durability of Maintenance Infliximab Therapy in Children with Crohn's Disease: Are Gender and Concomitant Immunomodulators More Important Than We Thought? Gastroenterology. 2014;146(5): S-25-S-26. Hofmekler T, Sauer C, Gillespie S, McCracken C, Bertha M, Walters TD, Denson L, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh JR, Pfefferkorn MD, Otley AR, Heyman MB, Leleiko NS, Baker SS, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens MC, Mack DR, Oliva-Hemker M, Patel AS, Kirschner BS, Moulton DE, Cohen SA, Kappelman M, Hyams JS, and Kugathasan S. l. Clinical Outcome and Prediction of Final Diagnosis in Pediatric Inflammatory Bowel Disease Unclassified (IBD-U) Patients. Gastroenterology. 2014; 146(5): S-779. Jensen ET, Cook S, Allen JK, Brookhart MA, Kappelman M, Dellon ES. What Is the Burden of GI Illness in the United States? It Depends on How You Ask. Gastroenterology. 2014; 146(5): S-561-S-2. Jensen ET, Martin CF, Kappelman M, Dellon ES. Health Care Utilization and Costs Related to Eosinophilic Esophagitis in the United States Represent a Significant Burden of Disease. Gastroenterology. 2014; 146(5): S-666. Lange A, Frøslev T, Erichsen R, Kappelman M. Early Life Exposures and Potential Subsequent Risk of Crohn's Disease: A Danish National Birth Cohort. Gastroenterology. 2014; 146(5): S-212-S-3. Markowitz J, Lerer T, Morganstern J, Deslandres C, Tomer G, Schaefer M, Kugathasan S, Faubion WA, Kappelman M, Sudel B, Hitch M, Keljo DJ, Grossman AB, Carvalho RC, Leleiko NS, Saeed S, Oliva-Hemker M, Kay MH, Rosh JF, Pfefferkorn MD, Otley AR, Rick J, Mack DR, Cabrera J, Griffiths AM, and Hyams J. Long-Term Outcome of Children with Crohn's Disease: Results from a Large Multi-Center North American Inception Cohort. Gastroenterology. 2014; 146(5): S-170-S-1.


15

Buckley JP, Kappelman MD, Allen JK, Muppidi B, VanMeter SA, Cook SF. Analgesic and Psychiatric Co-Medication in Commercially Insured Pediatric Inflammatory Bowel Disease Patients. Pharmacoepidemiology and Drug Safety 2013; 22:332-332. Buckley JP, Kappelman MD, Allen JK, VanMeter SA, Cook SF. Polypharmacy among Medicaid Recipients with Inflammatory Bowel Disease. Pharmacoepidemiology and Drug Safety 2013; 22:460-461. Crockett S, Schectman R, Kappelman M. Topiramate Use Does Not Reduce Flares of Inflammatory Bowel Disease: A Retrospective Cohort Study. American Journal of Gastroenterology 2013;108: S511-S511. Jensen E, Martin C, Shaheen N, Kappelman M, Dellon E. How Common Are Eosinophilic GI Disorders? First Prevalence Estimates from a National Database. American Journal of Gastroenterology 2013;108: S9-S9. Long M, Kappelman M, Martin C, Chen W, Anton K, Sandler R. Role of Non-Steroidal Anti-inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease. American Journal of Gastroenterology 2013;108: S526-S526. Orman ES, Martin C, Kappelman MD, Hayashi PH, Long MD. Statins are Associated with a Decreased Risk of Variceal Bleeding in Compensated Cirrhosis. Hepatology 2013; 58:293A-294A. Dotson J, Crandall W, Zhang P, Forrest C, Bailey LC, Colletti R, and Kappelman M. O-005 Feasibility and Validity of the Pediatric Ulcerative Colitis Activity Index in Real-world Clinical Practice. Inflammatory Bowel Diseases 2013;19: S3 Dotson J, Kappelman M, Chisolm D, Crandall W. O-009 Healthcare Disparities in Hospitalized Children and Adolescents with Crohn's Disease: Is Race Associated with the Need for Readmissions? Inflammatory Bowel Diseases 2013;19: S6-S7 Herfarth H, Martin C, Sandler R, Kappelman M, Chen W, Jaeger E, and Long M. P-048 Prevalence of Gluten Free Diet and Symptom Improvement in Patients with Inflammatory Bowel Diseases in CCFA Partners Cohort. Inflammatory Bowel Diseases 2013;19: S45-S46 Kappelman M, Martin C, Long M, Stoeber E, Kamphaus T, Chen W, Goble L, Jaeger E, and Sandler R. O-007 Development of CCFA Partners Kids & Teens: An Internet-based Cohort of Pediatric IBD. Inflammatory Bowel Diseases 2013;19: S5 Long M, Cadigan J, Cook S, Kaufman D, Kuczynski K, Haldeman K, Sandler R, Martin C, Chen W, and Kappelman M. P-064 Perceptions of Patients with Inflammatory Bowel Diseases on Biobanking in the CCFA Partners Cohort. Inflammatory Bowel Diseases 2013;19: S53 Long M, Martin C, Schwartz J, Jaeger E, Kappelman M, Chen W, and Sandler R.P-047 Behavioral Strategies to Improve Cohort Retention Within CCFA Partners. Inflammatory Bowel Diseases 2013;19: S44-S45


16

Hoffenberg EJ, Fridge J, Leibowitz I, Tsou M, Dykes D, Kappelman M, Colletti R. Useof the Emergency Department in Pediatric Inflammatory Bowel Diseae. JPGN Vol 57, Supp 1, 2013 E63 Sunseri WM, Hyams JS, Lerer T, Mack DR, Griffiths AM, Otley AR, Rosh JR, Bousvaros A, Carvalho R, Grossman AB, Cabrera J, Pfefferkorn MD, Rick J, Leleiko NS, Hitch MC, Evans J, Oliva-Hemker M, Saeed SA, Kappelman M, Markowitz J, Keljo DJ: 831 Prospective Cohort Study of Methotrexate Use in Treatment of Pediatric Crohn Disease. Gastroenterology 2013; 144: S-146. Randell RL, Cook S, Wrennall CE, Long MD, Chen W, Martin CF, Anton K, Sandler RS, Kappelman M: 982 Validation of an Internet-Based Cohort of Patients with Inflammatory Bowel Diseases (CCFA Partners). Gastroenterology 2013; 144: S-180. Kappelman M, Bailey C, Crandall W, Zhang P, King E, Joffe MM, Colletti RB, Forrest CB: 830 Real-World Clinical and Comparative Effectiveness of Infliximab in Pediatric Crohn's Disease. Gastroenterology 2013; 144:S-146. Jones PD, Kappelman M, Martin CF, Chen W, Sandler RS, Long MD: Mo1351 Association Between Exercise and Future Flares in an Inflammatory Bowel Disease Population in Remission. Gastroenterology 2013; 144:S-644. Jensen ET, Martin CF, Shaheen NJ, Kappelman M, Dellon ES: Su1852 High Prevalence of Co-Existing Autoimmune Conditions Among Patients with Eosinophilic Esophagitis. Gastroenterology 2013; 144:S-491. Grossi V, Lerer T, Markowitz J, Griffiths AM, Evans J, Bousvaros A, Mack DR, Otley AR, Pfefferkorn MD, Rosh JR, Oliva-Hemker M, Saeed SA, Deslandres C, Carvalho R, Grossman AB, Keljo DJ, Kappelman M, Hitch MC, Sudel B, Rick J, Cabrera J, Faubion WA, Leleiko NS, Hyams JS: 692 Impact of Body Mass Index on Efficacy of Infliximab in Children with Inflammatory Bowel Disease. Gastroenterology 2013; 144:S-128. Dellon ES, Jensen ET, Martin CF, Shaheen NJ, Kappelman M: Su1843 The Prevalence of Eosinophilic Esophagitis in the United States: Estimates from a Large Administrative Database. Gastroenterology 2013; 144: S-489. Buckley JP, Kappelman M, Allen JK, VanMeter SA, Cook S: Su1057 The Burden of Comedication Among Inflammatory Bowel Disease Patients. Gastroenterology 2013; 144:S-388. Ananthakrishnan AN, Long MD, Martin CF, Sandler RS, Kappelman M: Mo1349 Sleep Disturbance and Risk of Relapse in Crohn's Disease and Ulcerative Colitis. Gastroenterology 2013; 144: S-643. Kappelman MD, Martin CF, Weinfurt K, Flynn K, Chen W, Anton K, Cross R, Long MD, Sandler RS. Sexual Interest and Satisfaction in an Internet Cohort of Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2012; 18, Suppl. 1.


17

Kappelman MD, Long MD, Martin CF, Chen W, Anton K, Sandler RS. An Update on the CCFA Partners Internet Cohort Study Inflamm Bowel Dis 2012; 18, Suppl 1. Long M, Kappelman M, Martin C, Chen W, Anton K, and Sandler R. A Randomized Trial of Electronic (E-mail) Prevention Messages within the CCFA Partners Cohort. Inflamm Bowel Dis 2012; 18, Suppl1. Long MD, Kappelman MD, Martin C, Sandler RS, Chen, W, Anton K, and Kappelman MD. Risk Factors for Depression in the Elderly Inflammatory Bowel Disease Population. Am J Gastroenterol 2012; 107:S686. Randell R, Ling MD, Martin CM, Sandler RS, Chen W, and Kappelman MD. Patient Perception of Chronic Illness Care Is Associated with Quality of Life in Inflammatory Bowel Diseases. Am J Gastroenterol 2012; 107:S662. Long MD, Herfarth H, Martin C, Sandler RS, and Kappelman MD. Increased Risk of Herpes Zoster among Patients with Inflammatory Bowel Disease. Am J Gastroenterol 2012; 107: S653. Benchimol EI, Cook S, Erichsen R, Bernstein CN, Wong J, Carroll CF, Froslev T, Martin CF, and Kappelman M. Su1010 International Variation in Medication Prescription Rates in Elderly Patients with Inflammatory Bowel Disease. Gastroenterology 2012;142: S-398-S-399. Benchimol EI, Erichsen R, Cook S, Bernstein CN, Wong J, Carroll CF, Froslev T, and Kappelman M. 1146 International Variation in Medication Prescription Rates in Children with Inflammatory Bowel Disease. Gastroenterology 2012;142: S-208. Burkam J, Crandall W, Bistrick S, King E, Pratt J, Kappelman M, and Colletti RB. 1148 Is There Seasonal Variation of Disease Activity in Pediatric-Onset Inflammatory Bowel Disease? Gastroenterology 2012;142: S-209. Cohen A, Lee DY, Long MD, Kappelman M, Martin CFF, Kinneer PM, Sandler RS, and Lewis JD. Sa1257 Dietary Patterns and Self Reported Associations of Diet with Symptoms of Inflammatory Bowel Disease. Gastroenterology 2012;142: S-256. Goyal A, Hyams JS, Lerer T, Leleiko NS, Otley AR, Griffiths AM, Evans J, Rosh JR, Stephens MC, Bousvaros A, Oliva-Hemker M, Mack DR, Ashai-Khan FN, Pfefferkorn MD, Carvalho R, Grossman AB, Hitch MC, Sudel B, Kappelman M, Saeed SA, Faubion WA, Kay MH, Schaefer M, Markowitz J, and Keljo DJ. 142 Prospective Multicenter Pediatric Cohort Study: Patients with Liver Enzyme Elevations in the First 3 Months After Diagnosis of Inflammatory Bowel Disease are at Increased Risk of Chronic Liver Disease. Gastroenterology 2012;142: S-37. Kappelman M, Froslev T, Erichsen R, Baron JA, Sandler RS, and Sorensen HT. Mo1992 Early Life Exposure to Antibiotics and Subsequent Risk of Crohn's Disease: A Danish National Birth Cohort. Gastroenterology 2012; 142: S-716. Kappelman M, Long MD, Martin CF, DeWalt DA, Lewis JD, Kinneer PM, and Sandler RS. Sa1253 Evaluation of the Patient Reported Outcomes Measurement Information System


18

(PROMIS) in a Large Cohort of Patients with Inflammatory Bowel Diseases. Gastroenterology 2012;142: S-255. Long MD, Farraye FA, Okafor PN, Martin CF, Sandler RS, and Kappelman M. Mo1697 Risk of Pneumocystis Jiroveci Pneumonia Among Patients with Inflammatory Bowel Disease. Gastroenterology 2012;142: S-662. Long MD, Martin CF, Sandler RS, and Kappelman M. Tu1255 Increased Risk of Pneumonia Among Patients with Inflammatory Bowel Disease. Gastroenterology 2012;142: S-786. Markowitz J, Evans J, Pfefferkorn MD, Griffiths AM, Keljo DJ, Mack DR, Carvalho R, Leleiko NS, Otley AR, Rosh JR, Stephens MC, Saeed SA, Ashai-Khan FN, Bousvaros A, Kay MH, Oliva-Hemker M, Grossman AB, Sudel B, Kappelman M, Dimmitt RA, Langton CR, and Hyams JS. Sa1884 Infliximab Versus Immunomodulator as First Maintenance Therapy in Children with Crohn Disease. Gastroenterology 2012; 142: S-349. G, Siegel CA, Spiegel BM, Allen JI, Cima RR, Colombel J-F, Dassopoulos T, Denson L, Dudley-Brown S, Garb A, Hanauer SB, Kappelman M, Lewis JD, Lynch I, Moynihan A, Rubin DT, Sartor RB, Schwartz R, Wolf DC, and Ullman TA. Sa1295 Development of Process and Outcome Quality Indicators for Inflammatory Bowel Disease (IBD). Gastroenterology 2012;142: S-266. Pfefferkorn MD, Lerer T, Mack DR, Evans J, Keljo DJ, Kay MH, Rosh JR, Otley AR, Stephens MC, Oliva-Hemker M, Leleiko NS, Bousvaros A, Carvalho R, Ashai-Khan FN, Grossman AB, Saeed SA, Hitch MC, Kappelman M, Sudel B, Faubion WA, Markowitz J, and Hyams JS. 141 Assessment of Durability of Infliximab Maintenance Therapy in Children with Crohn's Disease. Gastroenterology 2012; 142: S-37. Michael Kappelman, Carol Carr, Robert Sandler, and Joan Walsh. Adaptation of the assessment of chronic illness care survey for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17, Suppl 2. Michael Kappelman, Kristen Moore, Jeffery Allen, Suzanne Cook. Recent trends in the epidemiology of IBD in the U.S. Inflamm Bowel Dis. 2011;17, Suppl 2. Millie Long, Michael Kappelman, Christopher Martin, James Lewis, Patricia Kinneer, Robert Sandler Status of prevention in Patients with Inflammatory Bowel Diseases within the CCFA partner’s cohort Inflamm Bowel Dis. 2011; 17, Suppl 2. Millie Long, Kelly Nelson, Alexis Ponder, Kathleen Kollitz, Michael Kappelman. haracteristics of malignant melanoma in patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2011; 17, Suppl 2. Millie Long, Michael Kappelman, Christopher Martin, James Lewis, Patricia Kinneer, Robert Sandler. Development of an internet-based Cohort of patients with Inflammatory Bowel Diseases (CCFA Partners): Methodology and initial results. Inflamm Bowel Dis. 2011; 17, Suppl 2.


19

Millie Long, Michael Kappelman, Christopher Martin, James Lewis, Patricia Kinneer, Robert Sandler. Quality of life in patients with Inflammatory Bowel Diseases within the CCFA Partners Cohort. Inflamm Bowel Dis. 2011; 17, Suppl2. Michael Kappelman, Millie Long, Christopher Martin, James Lewis, Patricia Kinneer, Robert Sandler. Medication Adherence in Patients with Inflammatory Bowel Diseases within the CCFA Partners Cohort Inflamm Bowel Dis. 2011; 17, Suppl 2. Millie Long, Clare Pipkin, Christopher Martin, Hans Herfarth, Robert Sandler, Michael Kappelman. Increased risk of melanoma among patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2011; 17, Suppl 2. V. Martin, C. Langton, J. Markowitz, A. Griffiths, D. Mack, A. Otley, M. Oliva-Hemker, D. Keljo, R. Carvalho, J. Evans, M. Stephens, A. Bousvaros, M. Pfefferkorn, J. Rosh, C. Ashai-Khan, M. Kappelman, M. Kay, R. Dimmitt1, B. Sudel, W. Faubion, M. Schaefer, N. LeLeiko, and T. Lerer, Jeffrey Hyams. Evaluation of the use and safety of Infliximab in the Treatment of Pediatric IBD: A Multicenter Registry Experience. J Pediatr Gastroenterl Nutr 2011;53, Suppl 1. Kappelman M, Farkas DK, Erichsen R, Pedersen L, Sandler RS, Baron JA, Sorensen HT. Risk of solid organ and hematological malignancy in patients with inflammatory bowel diseases. Gastroenterol 2011; 140, Suppl 1.

Dorn SD, Wei D, Farley J, Shah ND, Shaheen NJ, Sandler RS, and Kappelman MD. Impact of the 2008-2009 Economic Recession on Colonoscopy Utilization Among the Insured. Gastroenterol 2011; 140, Suppl 1. Lee G, Kappelman MD, Boyle B, Colletti RB, King E, Pratt J, Crandall W. Are there gender differences in the clinical outcomes of pediatric inflammatory bowel disease? Gastroenterol 2011; 140, Suppl 1. Zeisler B, Lerer T, Markowitz J, Mack D, Griffiths AM, Bousvaros A, Keljo D, Rosh J, Evans J, Kappelman M, Otley A, Kay M, Grossman A, Samson C, Saeed S, Carvalho RS, Oliva-Hemker M, Faubion W, Sudel B, Pfefferkorn M, LeLeiko N, Hyams JS. Outcomes Following Aminosalicylate Therapy in Children Newly Diagnosed with Ulcerative Colitis: A Prospective Multi-Center Registry Experience. Gastroenterol 2011; 140, Suppl 1. Ofei S, Hyams Jeffrey, Lerer T, Carvalho R, Crandall W, Schaefer M, Machan JT, Langton CR, Mack DR, Evans J, Pfefferkorn MD, Griffiths AM, Otley A, Bousvaros A, Keljo DJ, Kay MH, Oliva-Hemker M, Kappelman M, Saeed SA, LeLeiko NS, Stephens MC, Grossman AB, Markowitz J, Rosh JR. Changing Trends in Pharmacologic Therapy of Pediatric Crohn’s Disease. Gastroenterol 2011; 140, Suppl 1. Markowitz J, LeLeiko NS, Keljo DJ, Mack DR, Evans J, Kappelman M, Oliva-Hemker M, Otley AR, Pfefferkorn MD, Rosh JR, Stephens MC, Carvalho R, Hyams JS. The Prometheus Crohn’s Prognostic Test Does Not Reliably Predict Complicated Crohn’s Disease in Children. Gastroenterol 2011; 140, Suppl 1.


20

Schaefer ME, Langton CR, Markowitz J, Mack DR, Evans JS, Pfefferkorn MD, Griffiths AM, Otley AR, Bousvaros A, Rosh JR, Keljo DJ, Carvalho RS, Kay MH, Oliva-Hemker M, Kappelman MD, Ashai-Khan F, Stephens M, Samson CM, Grossman AB, Dimmitt RA, Sudel B, Faubion WA, LeLeiko NS, Hyams JS. Post-Intestinal Resection Management of Pediatric Crohn’s Disease. Gastroenterol 2011; 140, Suppl 1. Boyle B, Kappelman M, Colletti R, Qureshi M, Baldassano R, Milov D, Margolis P, Bousvaros A, Crissinger K, D’Amico M, Day A, Denson L, Dubinsky M, Ebach D, Hoffenberg E, Kader H, Keljo D, Leibowitz I, Mamula P, Pfefferkorn M, and Crandall W. J Pediatr Gastroenterl Nutr 2010; 51, Suppl 2: E78. Patel H, Lerer T, Hyams J, Bousvaros A, Crandall W, Evans J, Faubion W, Griffiths A, Grossman A, Kappelman M, Kay M, Keljo D, Leleiko N, Mack D, Michail S, Oliva-Hemker M, Otley A, Pfefferkorn M, Rosh J, Saeed S, Samson C, Stephens M, Susel B, and Markowitz J. Outcome Following Aminosalicylate (5ASA) Therapy in Crohn’s Disease (CD). J Pediatr Gastroenterl Nutr 2010; 51, Suppl 2: E83. Peterson E, Runge T, Tolleson-Rinehart S, Crandall W, Colletti R, and Kappelman M. Analyzing the sustainability of a pediatric IBD quality improvement collaborative. Inflammatory Bowel Diseases 2010; 17: S37. Runge T, Peterson E, Tolleson-Rinehart S, Crandall W, Colletti R, and Kappelman M. Perceptions of participating in a pediatric IBD quality improvement network. Inflammatory Bowel Diseases 2010; 17: S59. Long MD, Crandall W, Leibowitz IH, Duffy L, del Rosario F, Kim SC, Integlia M, Berman J, Grunow J, Colletti RB, Schoen BT, Patel AS,Baron H, Israel E, Russell G, Ali S, Herfarth HH, Martin C, and Kappelman MD. The Prevalence and Epidemiology of Overweight and Obesity in Children with Inflammatory Bowel Disease. J Gastroenterol 2010; 105: S544. Crandall W, Kappelman M, Colletti RB, Denson L, Duffy LF, Grunow J, Kim SC, Leibowitz I, Patel AS, Schoen BT, Tomer G, Milov DE, Cohen SA, and Margolis P. 151 Improved Outcomes in a Quality Improvement Collaborative for Pediatric Ulcerative Colitis. Gastroenterology 2010; 138: S-29. Hyams JS, Lerer T, Mack DR, Bousvaros A, Griffiths AM, Rosh JR, Otley AR, Evans JS, Stephens M, Kay MH, Keljo DJ, LeLeiko NS, Saeed S, Crandall W, Michail S, Kappelman M, Samson CM, Sudel B, Oliva-Hemker M, Pfefferkorn MD, and Markowitz J. 506 Outcome Following Thiopurine use in Children with Ulcerative Colitis: A Prospective Multicenter Study. Gastroenterology 2010; 138: S-73. Kappelman M, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, Baron JA, and Sorensen HT. 762 The Association Between IBD and Venous Thromboembolism in Danish Children and Adults: A Population-Based Case-Control Study. Gastroenterology 2010; 138: S-105-S-106. Mack DR, Markowitz J, Lerer T, Griffiths AM, Evans JS, Otley AR, Bousvaros A, Pfefferkorn MD, Rosh JR, Crandall W, Michail S, Oliva-Hemker M, Kay MH, Samson CM, Keljo DJ,


21

Kappelman M, Stephens M, Grossman AB, Saeed S, LeLeiko NS, and Hyams JS. S1189 Upper Gastrointestinal Involvement in Pediatric Crohn's Disease: Experience of a Large Multicenter Inception Cohort. Gastroenterology 2010; 138: S-200. Palmer LB, Kappelman M, Porter CQ, Sandler RS, and Hayashi PH. 710 Screening for Hepatocellular Carcinoma in a Medicaid Cirrhotic Population: Opportunities for Improvement. Gastroenterology 2010; 138: S-796. Pfefferkorn MD, Langton CR, Mack DR, Otley AR, LeLeiko NS, Stephens M, Rosh JR, Oliva-Hemker M, Crandall W, Evans JS, Samson CM, Kappelman M, Michail S, Hyams JS, and Markowitz J. S2023 NOD2 Mutations and Presenting Clinical Characteristics of Crohn's Disease (CD) in Children. Gastroenterology 2010; 138: S-303. Rosh JR, Mohamed A, Dougherty K, Lerer T, Keljo DJ, Mack DR, Griffiths AM, Crandall W, Bousvaros A, Kay MH, Grossman AB, Pfefferkorn MD, Michail S, Stephens M, Samson CM, LeLeiko NS, Oliva-Hemker M, Saeed S, Kappelman M, Otley AR, Evans JS, Sudel B, Markowitz J, and Hyams JS. S2005 Clinical Effect and Changing Patterns of use of Methotrexate in the Treatment of Pediatric Crohn's Disease: A Multi-Center Experience. Gastroenterology 2010; 138: S-299. Candrilli SD, Kappelman MD, Karve SJ, Tennis P, Andrews EB, Massie SE, Belhorn TH, and Tolleson-Rinehart S. Comorbidity Burden among US Pediatric Patients with Systemic Lupus Erythematosus (SLE) and Inflammatory Bowel Disease (IBD). E-PAS 2009; 4332. Kappelman MD, Markowitz J, Bousvaros A, Carvalho RS, Crandall W, Evans J, Galanko JA, Griffiths AM, Keljo DJ, Kugathasan S, Langton CR, Leleiko NS, Mack DR, Otley AR, Pfefferkorn MD, Rosh JR, Tomer G, Hyams JS. Inter-center variation in the clinical outcomes of pediatric Crohn's disease. Gastroenterology, 2009; 136: A-30. Markowitz J, Mack DR, Leleiko NS, Otley AR, Evans JS, Pfefferkorn MD, Oliva-Hemker M, Crandall W, Rosh JR, Kappelman MD, Lerer T, Hyams JS. Anti-Cbir 1 is commonly detectable in children with ulcerative colitis, but does not predict disease course over the first 2 years of treatment. Gastroenterology 2009; 136: A-3654. Lund J, Sturmer T, Porter C, Sandler S, and Kappelman MD. Thiazolidinedione Use and Ulcerative Colitis Related Flares: A Claims Database Analysis. Am J Epidemiol 2009; 169: S13. Crockett S, Martin C, Porter C, and Kappelman, MD. Accutane Use is Associated with Inflammatory Bowel Disease: A Case Control Study Using Administrative Data. Am J Gastroenterol 2009; 104:S431–S484. Long MD, Herfarth H, Porter CQ, Sandler RS, and Kappelman MD. Incidence and Risk Factors for Non-Melanoma Skin Cancer in Patients with Inflammatory Bowel Disease. Am J Gastroenterol 2009; 104:S431–S484. Kappelman MD Goudie A, Crandall W, Larry E., Fairbrother G, Margolis P, Leibowitz I, Duffy L, Milov D, Kim S, Schoen B, Cohen S, Patel A, Grunow J, and Colletti R. A Rapid Pediatric


22

Crohn's Disease Activity Index for Quality Improvement and Observational Research. J Pediatr Gastroenterl Nutr, 2009; 49: E1-103. Kappelman MD, Galanko J, Porter C, and Sandler R. Association of Pediatric Inflammatory Bowel Disease with other Immune-mediated Diseases. J Pediatr Gastroenterl Nutr 2009; 49: E1-103. Kappelman MD, Galanko J, Porter C, and Sandler R. Fracture Risk in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterl Nutr 2009; 49: E1-103. Kelly M, Lichtman S, and Kappelman M. Inflammatory Bowel Disease in the Young. Inflammatory Bowel Diseases, 2009; 15: S1-65. Crockett S, Porter C, and Kappelman M. Is isotretinoin exposure associated with Inflammatory Bowel Disease? A Case Control Study. Inflammatory Bowel Diseases, 2009; 15: S1-65. Kappelman M, Puho E, Sandler R, Rubin D, Ullman T, Pederson L, Baron J, and Sorensen H. The association between IBD and Venous Thromboembolic Events in Danish children and adults: A population-based case-control study. Inflammatory Bowel Diseases, 2009; 15: S1-65. Crandall W, Kappelman M, Colletti R, Denson L, Duffy L, Grunow J, Kim S, Leibowitz I, Patel A, Schoen B, Tomer G, Milov D, Cohen S, and Margolis P. Improved outcomes in a quality improvement collaborative for Pediatric Crohn Disease. Inflammatory Bowel Diseases, 2009; 15: S1-65. Kappelman M, Crandall W, Colletti R, Leibowitz I, Duffy L, Milov D, Kim S, Schoen B, Patel A, Grunow J, Goudie A, Larry E, Fairbrother G, and Margolis P. A short pediatric Crohn’s Disease Activity Index for Quality Improvement and Observational Research. Inflammatory Bowel Diseases, 2009; 15: S1-65. Kappelman MD, Rifas-Shiman S, Porter CQ, Ollendorf DA , Sandler RS, and Finkelstein JA Costs of Treatment of Crohn's Disease and Ulcerative Colitis in United States Children and Adults. Gastroenterolgy 2008; 134(4):): A-155. Kappelman MD, Cohen, S.A, Crandall, W, et al., Accelerating improvement in the management of pediatric inflammatory bowel disease. Gastroenterology, 2008; 134(4): p. A-473. Kappelman MD, Cohen SA , Crandall W, Duffy, LF, Gold, BD, Grunow, J, Kim, SC, Leibowitz I, Margolis, P, Mehta, DI, Milov, DE, Moyer MS, Myers SK, Patel, AS, Schoen, BT, Sudel B, Bornstein JA, and Colletti RS. Improving Care of Pediatric Inflammatory Bowel Disease: Preliminary Results of a Multicenter Improvement Collaborative. E-PAS 2008:5625. Long MD, Porter CQ Sandler RS, and Kappelman MD. Utilization of Cervical Testing Among Women with Inflammatory Bowel Disease Am J Gastroenterol, 2008; S421. Knupp, J, Kim S, Sharpless V, Galanko J, Martic C, and Kappelman M. Impact of a pediatric IBD action plan on disease knowledge, patient experience, and self-efficacy. Inflammatory Bowel Diseases, 2008; 14: S 26-27.


23

Kappelman, MD, Porter CQ, and Finkelstein JA. Medication use and costs among U.S. children and adults with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2008; 14: S3. Palmer L, Porter CQ, and Kappelman MD. Diagnostic Ionizing Radiation Exposure in a Population-based Sample of Children with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2008; 14(S3): S4. Kappelman, MD, Rifas-Shiman, SL, Kleinman, K Ollendorf, D, Bousvaros, A, Grand, RJ, and Finkelstein, JA. Prevalence of Crohn’s Disease and Ulcerative Colitis in the United States. Gastroenterolgy 2007; 132 (4). Kappelman M, Margolis P, Moyer M, Cohen S, Gold B, Crandall W, Patel A, Mehta D, Milov D, Grunow J, Leibowitz I, Colletti R. The quality of care in pediatric inflammatory bowel disease: does the chronic care model work? J Pediatr Gastroenterol Nutr 2007; 45:e5. Kappelman MD; Bousvaros A; Hyams J; Markowitz J; Pfefferkorn M; Kugathasan S; Rosh J; Otley A; Mack D; Griffiths A; Evans J; Grand R; Langton C; Finkelstein J. Inter-Center Variation in the Initial Management of Children with Crohn Disease. Gastroenterolgy 2006; 130 (Suppl): A-12. Kappelman MD, Watkins JB, and Buie TM. Celiac Disease Presenting as Coagulopathy in a Child with Down Syndrome. Am J Gastroenterol, 2005; 100: S101. Other Publications: Jaff JC and Kappelman MD. Inflammatory Bowel Disease and Health Insurance. Your Digestive Health (patient newsletter) 2012, April 13. (stand-alone patient newsletter, published online no pages to provide, link is no longer live) Pfefferkorn M, Crandall W, and Kappelman M. “Inflammatory and Immunological Diseases involving the intestine,” NASPGHAN Guidelines for Training in Pediatric Gastroenterology 2010; 56: S19-S20. Teaching Activities Course Instructor: 2009- 2010 UNC School of Medicine 2nd year Clinical Epidemiology Course, small

group instructor, 50 contact hours per year Lectures: 2017 Lecture in Methods and Issues in Pharmacoepidemiology course (EPID 765)

entitled “Pragmatic Clinical Trials”


24

2013-Present 1 lecture each year in the QI in Healthcare and Public Health course (PUBH703) entitled “Integrating Quality Improvement and Research in a Pediatric IBD Learning Health System”

2007-Present 1-2 lectures per year to pediatric house staff. Topics include pediatric gastroenterology and clinical epidemiology

2007-Present 1 lecture per year to K30 program (EPID 805-806) about grant writing, career development, etc.

2007-Present 2-3 lectures per year to the UNC Digestive Disease Epidemiology Fellowship program

11/9/2012 Lecture to Epid 896 ““Surviving and Thriving in Academics” 8/7/2012 Lecture for Pediatric Fellow orientation entitled "Getting Started in

Research” 8/10/2011 Lecture for Pediatric Fellow orientation entitled "Advanced Concepts in

Evidence-based Medicine” 2006-2007 Case discussion leader for Harvard Medical School 2nd year GI

pathophysiology course Grand Rounds at UNC: 4/30/2015 Integrating Quality Improvement and Research in a Learning Health System

for Pediatric Inflammatory Bowel Disease. UNC Institute for Healthcare Quality Improvement (IHQI)

11/7/2013 “Beyond the Clinical Trial: Using Real World Data to Drive Discovery and Improve Care Delivery for IBD”

2/24/2011 “Isotretinoin and IBD: Perspectives from a Pediatric Gastroenterologist” UNC Department of Pediatrics, Stony Brook

2009 “Pediatric Crohn’s Disease: Does it matter where children go for care” UNC Department of Pediatrics

Grand Rounds outside UNC: 7/27/2016 Division of Gastroenterology, Department of Internal Medicine, University

of Maryland School of Medicine, Baltimore, MD “Using Real-World Data to Drive Discovery and Improve Care Delivery for

Inflammatory Bowel Disease” 4/21/2016 Department of Pediatrics, Children’s Hospital of Pittsburgh, Pittsburgh, PA

“Beyond the Clinical Trial: Using Real-World Data to Drive Discovery and Improve Care Delivery for Inflammatory Bowel Disease”

11/11/2015 Department of Gastroenterology, University of Manitoba, Winnipeg, MB,

Canada


25

“The Crohn's and Colitis Foundation of America Patient Powered Research Network”

11/11/2015 Department of Pediatrics, University of Manitoba, Winnipeg, MB, Canada “Integrating Clinical Care, Quality Improvement, and Research in a

Pediatric IBD Learning Health System: The ImproveCareNow Experience” 9/16/2015 Department of Pediatrics, State University of New York at Stony Brook

“Antibiotics and Risk of Pediatric Crohn’s Disease” 4/23/2013 Division of Gastroenterology, Icahn School of Medicine at Mount Sinai "Beyond the Clinical Trial: Using Real-World Data to Drive Discovery and

Improve Care Delivery for Inflammatory Bowel Disease” 4/16/2012 Texas Children’s Hospital, Division of Gastroenterology “Can Health Insurance Data Teach us about Inflammatory Bowel Disease” 11/05/2010 Duke University, Department of Dermatology “Isotretinoin and IBD: Perspectives from a pediatric gastroenterologist” 2010 Moses Cone Department of Pediatrics “Pediatric Crohn’s Disease: Does it matter where children go for care” 2009 Nationwide Children’s Hospital, Columbus, OH “Pediatric Crohn’s Disease: Does it matter where children go for care” Continuing Education Lectures at UNC: 2017 Triangle CER Symposium, “Pragmatic clinical trials for pediatric

comparative effectiveness research”, April 11, 2017 2016 PharmaSci 2016: Addressing Methodological and Ethical Issues in Pediatric

Medication Safety Research, UNC Eshelman School of Pharmacy, “Engaging Children and Parents on Study Teams”, May 13, 2016

2013 UNC Update in Inflammatory Bowel Diseases “What can we learn from

epidemiology for IBD therapy in 2013?” 2011 UNC Update in Inflammatory Bowel Diseases “Quality control in IBD-

should we even care?” 2008 Update in Gastroenterology and Hepatology: Applying Sound Principles in

Daily Practice “The Adolescent with IBD: customizing care for a lifelong illness”

Continuing Education Lectures outside UNC:


26

2017 Harvard Medical School Advances in Pediatric Gastroenterology, Hepatology, and Nutrition. Boston, MA. “Anti-TNF therapy in IBD: Monotherapy or Combination Therapy?” June 2, 2017

2016 Crohn’s and Colitis Foundation Annual Meeting. “How should methotrexate

be used in our pediatric IBD patients?” December 10, 2016 2016 Leading Change in Pediatric IBD, Course Director and lecturer on

“ImproveCareNow: Integrating Clinical Care, Quality Improvement, and Research in a Pediatric IBD Learning Healthcare System”, Barcelona, Spain, June 24-25, 2016

2015 Crohn’s and Colitis Foundation Annual Meeting. “Why does chronic

narcotic use in pediatric IBD patients occur and what are the consequences?” Orlando, FL. December 12, 2015

2015 Patient METRICs in IBD meeting. “Translating theory into practice:

Measuring quality in ImproveCareNow” Vienna, Austria, December 3, 2015 2015 Panelist, Town Hall on Privacy and Security, Health Datapalooza, June 2,

2015, Washington D.C. 2015 Selection and Use of Patient Reported Outcomes in a Patient Powered

Research Network. January 8, 2015. NIH Collaboratory Workshop on Patient Reported Outcomes. Baltimore, MD.

2014 Selection and Use of Patient Reported Outcomes in a Patient Powered

Research Network. July 9, 2014. Harvard Scalable Infrastructure for a Learning Health System Workshop. Boston, MA.

2014 2nd Annual Coumbia University Pediatric IBD Confernece. “Early Life

Exposure to Antibiotics and Subsequent Risk of Crohn’s Disease” New York, New York. June 5, 2014

2014 Crohn’s and Colitis Foundation of America IBD 2020 Quality of Care

Meeting. “Different approaches to improving quality in IBD”. New Orleans, LA. May 17, 2014

2014 Canadian Digestive Disease Week Meeting. “Quality Improvement: Is it for

payers or patients” Toronto, Canada. February 9, 2014 2014 iHealth conference (Academy Health and American Medical Informatics

Association meeting). “Fishbowl lnnovations in Pediatric Quality Improvement: The ImproveCareNow Experience” Orlando, FL. February 1, 2014

2014 Leading Change in IBD conference. “Leading the Way Across the USA”.

Barcelona, Spain. January 17, 2014


27

2013 Crohn’s and Colitis Foundation Annual Meeting. “Beyond Accountability:

Using QI to change clinical outcomes”. Hollywood FL. December 13, 2013 2013 IBD 2020 conference. “Pediatric IBD Quality Improvement in the United

States: The ImproveCareNow Experience”. Oxford, UK. September 11, 2013

2013 International Organization for the Study of IBD. “CCFA Partners Initiative”

New York, New York. April 12, 2013 2013 Epidemiologic Research in IBD: Designing a Surveillance Program for IBD

in the United States (CCFA sponsored). ““The epidemiology of IBD in children: is the count accurate?” and “Using administrative health data from third party payers for descriptive epidemiology of IBD” Philadelphia, PA. February 25, 2013.

2012 Digestive Diseases Week Meet the Professor “Using Large Datasets for IBD

Research” 2012 North American Society for Gastroenterology, Hepatology, and Nutrition

Single Topic Symposium on Pediatric IBD. “A Learning Healthcare System: Integrating Clinical Care, Quality Improvement, and Research”

2012 North American Society for Gastroenterology, Hepatology, and Nutrition

Single Topic Symposium on Pediatric IBD. “Fellow and Career Development Awards”

2012 Inflammatory Bowel Disease: The Art and Science in the Diagnosis and

Treatment in 2012. “IBD Epidemiology: What’s new?” Boston, MA. September 28, 2012

4/9/2011 16th Annual Education Crohn’s and Colitis Symposium, Chicago, IL “Burden of IBD: How Big is the Problem and What Are the Reasons for It?”

and “Improving Outcomes in Pediatric IBD” 2011 Advances in Inflammatory Bowel Disease (CCFA sponsored) “Use of pharmaco-epidemiology to identify drug safety issues and future

therapeutic options” Hollywood, FL. 2010 IBD Clinical Trials Course (CCFA sponsored) “Burden of Disease: Incidence, Prevalence, Natural History, & Costs” 2010 North American Society for Pediatric Gastroenterology, Hepatology, and

Nutrition Postgraduate Course “A New Approach to the Management of Pediatric IBD” 2010 Advances in Inflammatory Bowel Disease (CCFA sponsored)


28

“Improving the quality of care for the pediatric IBD patient” and “Environmental factors: Is pediatric IBD a man-made condition?”

2009 North American Society for Pediatric Gastroenterology, Hepatology, and

Nutrition Meet the Professor “IBD Research: A guide for fellows and junior faculty” 2008 Pediatric IBD Network for Research and Improvement Collaborative

Learning Session (Cincinnati Children’s Hospital Medical Center) "Understanding and Use of IBD Disease Activity Indices"

2007 Digestive Disease Week Meet the Professor “Data Sources for Epidemiological Studies of IBD” Clinical Teaching: 2007-Present Clinical teaching of medical students and pediatric housestaff as inpatient

attending, 3-6 weeks per year 2001-2007 Clinical supervision and teaching of medical students and house staff (during

residency and fellowship) Research Mentoring: 2007-Present Research mentoring of medical students, MPH students, residents, fellows,

and junior faculty. Thesis committee for two students in the Pharmacoepidemiology program in the School of Public Health. Training tables and letters of reference on file.

Other Teaching and Supervision: 2001-2006 Harvard University Premedical Advisor for Winthrop House. In this position, I was responsible for advising and preparing Dean's letters

for 2-4 undergraduate pre-medical students per year. Grants: Active: 288053 (PI Kappelman) 1/1/2016-12/31/2017 $200,000 8% Effort Crohn's and Colitis Foundation of America, Inc CCFA Partners An Internet-Based Cohort Study Role: Co-Principle Investigator (PI Long) 8/1/16-7/30/2019 Patient-Centered Outcomes Research Institute $66,748 2% effort Harnessing PCORnet to Study Comparative Effectiveness and Safety of Biologic Therapies


29

Role: co-investigator (PI Sandler) 8/1/16-7/30/2019 Patient-Centered Outcomes Research Institute $408,882 2% effort Comparative Effectiveness of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients with Crohn's Disease Role: co-investigator (PI Long) 3/1/13-7/30/2019 Patient-Centered Outcomes Research Institute $42,700 1% effort Healthy Mind Healthy You Role: co-investigator PCS-1406-18643 (Kappelman) 8/01/15-1/31/21 $7,885,900 27.4% Effort Patient-Centered Outcomes Research Institute Anti-TNF Monotherapy versus Combination Therapy with Low Dose Methotrexate in Pediatric Crohn’s Disease Role: Principal Investigator 2016PG-IBD003 (Kappelman) 4/1/2016-3/31/2019 $678,321 1% Effort The Helmsley Charitable Trust Anti-TNF Monotherapy versus Combination Therapy with Low Dose Methotrexate in Pediatric Crohn's Disease Role: Principal Investigator 1501-26653 (Kappelman) 10/01/15-09/30/18 $1,624,392 35% Effort Patient-Centered Outcomes Research Institute The CCFA Partners Patient Powered Research Network Role: Principal Investigator 3210940919-XX 09/30/2015 – 09/29/2019 $4,169,995 10% Effort National Institute of Arthritis and Musculoskeletal and Skin Diseases The Child-Centered Outcomes in Practice and Research (COPR) Center of Excellence: Strengthening the Clinical Validity Evidence Base for PROMIS Measures in Chronically Ill Children Role: Principal Investigator of a component project 1U19AR069522 9/30/2015-9/29/2019 (PI Reeve) $2,936,800 5% Effort National Institute of Arthritis and Musculoskeletal and Skin Diseases Enhancing Clinical Meaningfulness and Usefulness of PROMIS Pediatric Measures Via Validation in Children and Adolescents with Rheumatic Disease, Cancer, or Inflammatory Bowel Disease Role: co-investigator C0168Z02 (PI Kappelman) 8/11/2019-8/10/19 $306,447 1% Effort Janssen Biotech, Inc.


30

A Multicenter, Prospective, Longterm, Observational Registry of Pediatric Patients with IBD Role: Site Principal Investigator 133635 (PI Margolis) 09/13/2015-9/12/2018 $51,909 3.41% Effort Cincinnati Childrens Hospital Medical Center ImproveCareNow: A Learning Health System for Children with Crohn’s Disease and Ulcerative Colitis Role: co-investigator No Number (PI Kappelman) 5/1/2016-6/30/2017 $27,000 1% Effort SICKKIDS Pro-KIIDS and NEOPICS Retrospective Cohort Study of Very Early Onset IBD (VEOIBD) Role: Site Investigator Pending: UNC CTSA Renewal Role: co-director of Community Engagement Core Completed: T057551 (PI Kugathasan) 7/1/2009-6/30/2017 $14,400 1% Effort Emory University/Crohn’s and Colitis Foundation of America, Inc. Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn’s Disease Role: Site Principal Investigator 1U01 DK095745 (PI Hyams) 6/1/2012-9/10/2017 $26,100 1% Effort NIH/Connecticut Children’s Medical Center Subcontract to UNC-CH Predicting Response to Standardized Pediatric Colitis Therapy (PROTECT) Role: Site Principal Investigator 288053 (PI Kappelman) 4/15/2013-12/31/2016 $359,189 4.4% Effort Crohn's and Colitis Foundation of America, Inc CCFA Partners-Pediatrics: An Internet-Based Cohort Study Role: Principle Investigator 3374 (PI Sandler) 1/1/2011-12/31/2016 $800,000 4.4% Effort Crohn's and Colitis Foundation of America, Inc Patients as Partners: An Internet-Based Cohort Study Role: Investigator 13-5144 (PI Sartor) 07/01/2013-06/30/2016 SHARE: Translational Studies in Inflammatory Bowel Disease (PI Sartor) Leona M and Harry B Helmsley Charitable Trust $288,029.60 Role: Investigator 5630622 (PI Kugathasan) 3/1/2011-2/28/2015 $57,307 1% Effort


31

NIH/Emory University Subcontract to UNC-CH Gene Discoveries in Subjects with Crohn’s Disease of African Descent Role: Site Principal Investigator No Number (PI Kappelman) 11/26/13-11/25/15 $453,750 10% Effort GlaxoSmithKline CCFA Partners: Expansion of Cababillities Via Record Linkages and Patient Reported Outcomes Research to Enable Observational Research Role: Principal Investigator 133635/3100377556 (PI Margolis) 8/1/2014-9/13/2015 CCHMC/Patient-Centered Outcomes Research Institute $26,909 The ImproveCareNowNetwork: A Learning System for Children with Crohn’s Disease and Ulcerative Colitis Role: Investigator No Number 08/01/2014-5/30/2015) Crohn’s and Colitis Foundation of America, Inc $35,036 IBD Exchange Integration and Transition Award Role: Investigator No Number (PI Kappelman) 03/01/14-08/31/15 $997,554 30% Effort Patient-Centered Outcomes Research Institute The CCFA Partners Patient Powered Research Network Role: Co-PI and Scientific Director No number (PI Kappelman/Sandler) $196,480 1% effort GlaxoSmithKline, Inc CCFA Partners Cohort Biospecimen Repository Role: Co-Principal Investigator Dates: 1/1/2013-1/1/2014 1K08 DK088957-01 (PI Kappelman) $457,198 75% effort NIH/NIDDK Exposure to antibiotics during infancy and subsequent risk of Crohn's disease Role: Principal Investigator Dates: 4/18/2011-3/31/2014 1R01HS020024-01 (PI Hutton) $110,695 0% effort* NIH/CCHMC Subcontract to UNC-CH Building Modular Pediatric Chronic Disease Registries for QI and CE Research Role: Investigator/Site Principal Investigator Dates: 9/30/2010-9/29/2013 *project effort nested within K08 award No number (PI Crockett) $56,343 Broad Foundation


32

Effect of topiramate on severity of inflammatory bowel disease: exploratory study of a potentially novel therapeutic agent using administrative claims data Role: Investigator/ Mentor Dates: 7/1/2012-6/30/2013 2564 (PI Kappelman) $125,588 0% effort* Crohn's and Colitis Foundation of America, Inc Benchmarking and the chronic care model for pediatric Crohn’s disease Role: Principal Investigator Dates: 7/1/2010-6/30/2013 *project effort nested within K08 award S349340 (PI Kugathasan) $37,900 1% effort CCFA/Emory University Subcontract to UNC-CH CCFA Pediatric Crohn's Disease Risk Stratification Study A prospective, observational cohort study of 1000 Children with newly diagnosed Role: Site Principal Investigator Dates: 7/1/2009-6/30/2013 No number (PI Kappelman/Sandler) $64,000 1% effort GlaxoSmithKline, Inc Validation of the CCFA Partners Cohort Role: Co-Principal Investigator Dates: 6/13/2012-6/12/2013 14CLPED (PI Kappelman) $14,299 1% effort Adolor Corporation Investigation of the Natural History of Recovery of Pediatric Patients with Crohn’s Disease Undergoing Bowel Resection: A Multicenter Cohort Study Role: Principal Investigator Dates: 3/1/2012-2/28/2013 No number (PI Kappelman) $4,985 0% effort UNC-CH/University Research Council Infant Feeding, antibiotic exposure, and hospital delivery practices as risk factors for eosinophilic esophagitis: A pilot/feasibility study. Role: Principal Investigator Dates: 12/1/2010-11/30/2012 10KR51013 (PI Crockett) $10,000 Project Title: Do Statins Reduce Flares of Inflammatory Bowel Disease? A Retrospective Cohort Study Role: Mentor Project Period: 2/01/2010–1/31/2011 5-KL2-RR025746-02 (PI Pisano)


33

NIH/NCRR UNC Translational and Clinical Sciences Institute - Mentored Career Development Component (KL2) A national consortium with the goal of transforming how clinical and translational research is conducted, ultimately enabling researchers to provide new treatments more efficiently and quickly to patients. Role: Clinical Research Scholar 2008 - 2010 P30 DK34987-21 (PI Sandler) $18,500 Digestive Disease Research Core Center (Center for Gastrointestinal Biology and Disease) Role: Recipient of pilot and feasibility award Dates: 2007-2008

K12 RR023248-04 (PI Orringer) UNC Multidisciplinary Clinical Research Career Development Program This grant was merged into our institutional CTSA as a KL2. Role: Clinical Research Scholar Dates: 2007-2008 5T32DK007477-23 (PI Lencer) Training in Pediatric Gastroenterology and Nutrition Role: Fellow Dates: 2006-2007 5T32HS000063-13 (PI Goldmann) Child Health Services Research Training Program Role: Fellow Dates: 2005-2006 Professional Service: Committees to Discipline: 2017 Member of Canadian Association of Gastroenterology (CAG) Clinical Practice

Guideline (CPG) for the Management of Pediatric Crohn’s Disease Working Group

2017-Present Organizing Committee, Crohn’s and Colitis Congress (national meeting) 2015-Present Chair, Crohn’s and Colitis Foundation of America Pediatric Initiatives Committee 2011-Present Crohn’s and Colitis Foundation of America National Scientific Advisory Council 2010-Present Improve Care Now Pediatric IBD Quality Improvement Collaborative, Executive

Committee (Strategy Council as of 2015) 2014-2015 American Gastroenterological Association Institute Quality Measures Committee 2013-2015 U.S. News & World Report Best Children's Hospitals Gastroenterology & GI

Surgery Working Group


34

2012-2015 Crohn’s and Colitis Foundation of America, Research Initiatives Committee member

2011-2015 Co-Chair, Crohn’s and Colitis Foundation of America IBD Professional Education Committee

2010-2015 Crohn’s and Colitis Foundation of America IBD Quality Improvement Steering Committee

2007-2015 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, IBD Committee member

2013-2014 Co-Chair, Crohn’s and Colitis Foundation of America IBD Exchange Patient Oriented Research Committee

2011-2014 Co-Chair, North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and American Gastroenterological Association Pediatric IBD Quality Measures Working Group

2013 Center for Disease Control/ Crohn’s and Colitis Foundation of America IBD Surveillance Planning Group

2011-2012 Co-Chair, Crohn’s and Colitis Foundation of America 2012 Challenges in IBD Epidemiology/Environmental Factors Working Group

2009-2012 Crohn’s and Colitis Foundation of America Developing Quality Indicators (DQI) for IBD

2008-2012 CCFA Pediatric Affairs Committee 2007-2012 CCFA Camp Oasis Strategic Planning Committee 2009-2010 AGA Institute Inflammatory Bowel Disease Performance Measures Working

Group 2008-2010 Improve Care Now Pediatric IBD Quality Improvement Collaborative, Research

Committee Chair 2005-2007 Children's Hospital Boston Pediatric Gastroenterology Fellowship Procedure

Committee 2004-2007 North American Society for Pediatric Gastroenterology, Hepatology, and

Nutrition, Fellows Committee member 2001-2002 Massachusetts General Hospital Pediatric Residency Curriculum Committee 1998-1999 Washington University Board of Trustees 1997-1999 Washington University School of Medicine Committee for Medical Education Editorial Appointments: 2009-2016 Section editor, Inflammatory Bowel Diseases 2010-2013 Editorial Board, Clinical Gastroenterology and Hepatology


35

Committees within UNC-Chapel Hill: 2017-Present Department of Pediatrics Promotions Advisory Committee (PAC) 2015-Present Faculty, UNC Institute for Healthcare Quality Improvement (IHQI) 2010- Present Department of Pediatrics Faculty Development Committee 2010-Present UNC Pediatric Residency QI Program Steering Committee 2008-Present Pediatric Center for Clinical Excellence Faculty 2007-Present UNC Pediatric Inflammatory Bowel Diseases Quality Improvement program,

Physician Leader (co-leader after 2015) 2012 Department of Pediatrics Strategic Planning Committee 2011-2012 Interviewer, UNC Digestive Disease Epidemiology Program 2007-2008 UNC Patient Access, Care, and Efficiency Committee (PACE), Physician

Champion Peer review activities: 2017 AGA Institute's abstract review process for DDW 2017, IMIBD IBD

Epidemiology 2016 Crohn’s and Colitis Foundation of America Advances in IBD abstract reviewer 2015 AGA Institute's abstract review process for DDW 2016, IMIBD IBD

Epidemiology 2014 AGA Institute's abstract review process for DDW 2015, IMIBD IBD Quality of

Care section 2014 Crohn’s and Colitis Foundation of America Advances in IBD abstract reviewer 2013 AGA Institute's abstract review process for DDW 2014, IMIBD IBD

Epidemiology section 2013 Crohn’s and Colitis Foundation of America Advances in IBD abstract reviewer 2012 AGA Institute's abstract review process for DDW 2013, IMIBD IBD

Epidemiology section 2012 Crohn’s and Colitis Foundation of America Advances in IBD abstract reviewer 2011 AGA Institute's abstract review process for DDW 2012, IMIBD IBD

Epidemiology section 2010 AGA Institute's abstract review process for DDW 2011, IMIBD IBD

Epidemiology section 2009 AGA Institute's abstract review process for DDW 2010, IMIBD IBD

Epidemiology and Natural History section


36

Ad hoc grant reviewer for the following foundations: 2017 UNC Children’s Promise Grants 2017 UNC TraCS/ Carolinas Collaborative Pilot Grants 2017 UNC Institute for Healthcare Quality Improvement 2017 Canadian Institutes of Health Research (CIHR) 2008-Present Broad Medical Foundation 2012-2013 French National Research Agency 2011 & 2017 Carolina Medical Student Research Program Study Section 2010-2012 IBD Working Group 2010-2011 The Physicians' Services Incorporated Foundation 2010 Canadian Crohn’s and Colitis Foundation 2009 Dutch Digestive Foundation 2008 Alberta Children's Hospital Foundation 2007 Crohn's and Colitis Foundation of America (epidemiology review committee) Ad hoc reviewer for the following peer-review journals: 2007-Present JAMA, Gastroenterology, Clinical Gastroenterology and Hepatology, American

Journal of Gastroenterology, Gut, Journal of Pediatrics, Pediatrics, Inflammatory Bowel Disease, Digestive Diseases and Sciences, and Journal of Crohn's and Colitis.

Moderator at Scientific Meetings: 2016 CCFA Advances in IBD: Pediatric Session III 2015 CCFA Advances in IBD: “Stump the panel: Submitted cases selected for

presentation and discussion” 2014 North American Society for Pediatric Gastroenterology, Hepatology, and

Nutrition Annual Meeting, “Hot Topics in IBD”, Atlanta, GA 2014 Digestive Disease Week, IBD: Epidemiology of IBD, Chicago, IL 2013 Digestive Disease Week, IBD: Epidemiology of IBD, Orland, FL 2012 North American Society for Gastroenterology, Hepatology, and Nutrition Single

Topic Symposium on Pediatric IBD. “Developing a Research Career in Pediatric IBD” Salt Lake City, UT

2012 Digestive Disease Week, IBD: Pediatric IBD: Clinical Translational 2012 Digestive Disease Week, IBD: Epidemiology of IBD


37

2011 CCFA Advances in IBD: “Stump the panel: Submitted cases selected for presentation and discussion”

2011 Digestive Disease Week, IBD: Epidemiology and Outcomes 2010 CCFA Advances in IBD: Improving the quality of the care of our patients 2010 Digestive Disease Week, Natural History and Outcomes of IBD session Community Service Related to Professional Work: 2013-Present Crohn’s and Colitis Foundation of America Triangle Leadership Committee 2010-2013 Crohn’s and Colitis Foundation of America Raleigh/Durham Missions Committee 2006-2010 Crohn’s and Colitis Foundation of America Camp Oasis—camp doctor 1997-2000 Medical Education Representative, Washington University School of Medicine 1997-1999 Founder and President, Pediatric Outreach Project, Washington University School

of Medicine, St. Louis, MO 1996-1998 Students Teaching AIDS to Students: Instructor and Student Coordinator,

Washington University School of Medicine, St. Louis, MO Reflective Statement: As a pediatric gastroenterologist and digestive disease epidemiologist, I am dedicated to a career in clinical scholarship including 1) providing outstanding clinical care to children and young adults with inflammatory bowel disease (IBD), 2) conducting rigorous epidemiological and health services research related to these conditions, 3) teaching and mentoring the next generation of physicians and scientists, and 4) performing professional service and patient advocacy.

Research Statement

My research interests have largely focused on using real-world data to 1) define the burden of IBD (prevalence, costs, healthcare utilization, quality of life, disease complications), 2) elucidate the risk factors for developing IBD, 3) study the safety, effectiveness, and comparative effectiveness of different treatment options, and 4) measure and improve the quality of care delivered to this patient population.

I have been continuously funded to pursue these research areas since joining the UNC faculty in August 2007. Three career development awards (UNC KL2, Crohn’s and Colitis Foundation of America (CCFA), and NIDDK K08) have provided me with substantial protected time to develop methodological expertise and foster collaborations within the UNC community,


38

nationally, and internationally. Many of these collaborations have led to multi-center observational clinical and translational studies, for which I have served as a co-investigator or UNC site PI, including the CCFA Funded Risk Stratification study (Kugathasan, Emory, PI), the NIDDK funded PROTECT study (U01, Hyams, UConn, PI), a NIDDK funded genetics study (R01, Kugathasan, Emory, PI), and the AHRQ funded IBD Enhanced Registries study (R01, Hutton, CCHMC, PI).

More recently, I have collaborated with my mentor, Dr. Robert Sandler, to create the CCFA Partners internet cohort of adult patients with IBD. This novel research program concentrates on patient reported exposures, health behaviors, and outcomes and complements many of the studies using administrative data or multi-center registries discussed above. As I have grown in independence, I received an investigator-initiated, industry-funded award to perform a validation and biobanking study of this cohort (co-PI with Sandler, $260,480 direct costs). Subsequently, I received my first independent funding as the PI on a CCFA funded grant to establish a pediatric internet cohort study ($360,000 direct costs).

As I have grown more independent, I have leveraged and expanded these cohorts with 3 industry contracts from GlaxoSmithKline (approximately $650,000 total costs). In 2014-2015, I led (co-PI and Scientific Director) the transformation of the CCFA Partners cohort study into a Patient Powered Research Network, funded by the Patient Centered Outcomes Research Institute as part of the PCORnet national comparative effectiveness research infrastructure ($1,000,000 total costs). Currently, I am the PI recently awarded Phase II continuation award ($1.6 total costs).

In addition to these innovative observational studies, I have developed a second focus on interventional clinical trials. This includes serving as PI for a PCORI funded large pragmatic clinical trial to compare the effectiveness of anti-TNF monotherapy versus combination therapy with oral methotrexate. This $7.9 million project is expected to enroll 425 children, making it the largest pediatric IBD clinical trial in history.

In addition to my track record of career development and independent funding described above, additional evidence of national and international recognition includes my receipt in 2007 of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Young Clinical Investigator Award. Additionally, my publication record includes over 70 published research articles over the last 10 years along with over 20 review articles, editorials, and book chapters. I have been an invited speaker and/or session moderator at a number of national meetings, including annual meetings of NASPGHAN, the CCFA, and the American Gastroenterological Association (AGA). Additionally, I have served as a Visiting Professor and delivered Grand Rounds lectures at a number of universities nationally and internationally. I have become increasingly involved in peer review activities, including serving on the editorial board of two journals [Clinical Gastroenterology and Hepatology (Impact Factor 5.6) and Inflammatory Bowel Diseases (Impact Factor 4.9)], serving on a number of national and international grant review committees, serving on abstract review committees for the CCFA and


39

AGA annual meetings, and reviewing manuscripts for all major gastroenterology and pediatric journals.

Recently, a number of scientific leadership opportunities have allowed me to help shape the national research agenda for IBD. I co-chaired the Epidemiology working group of the CCFA directed Challenges in IBD Initiative, charged with providing a roadmap for prioritizing the foundation’s research investments. Additionally, I have served on an advisory committee to the CDC to help develop a national IBD surveillance program and was one of three scientists involved in planning the Crohn’s and Colitis Foundation of America’s large multidisciplinary, multi-institutional collaborative research infrastructure (IBD Plexus).

In the future, I plan to continue to both independent and collaborative patient-oriented and translational research in the area of IBD. My specific plans include 1) further establishing the research infrastructure to collect and integrate real-world data across various sources (administrative, electronic health record, clinical registry, and patient-reported), 2) use this infrastructure to conduct observational and interventional studies of the clinical and comparative effectiveness (and safety) of existing and emerging therapeutic strategies, and 3) collaborate with basic researchers to design studies that capitalize on this infrastructure to support translational research.

Teaching Statement

My educational responsibilities reflect the various aspects of my academic pursuits and consist of clinical teaching, lecturing and small-group teaching (medical school, post graduate training, and continuing medical education), and individual mentoring of students, trainees, and young professionals. I routinely teach residents and medical students while attending on clinical service or in clinic. Inpatient-based teaching consists of formal lectures, informal discussions and impromptu teaching. I was a small group section leader in the UNC 2nd year Clinical Epidemiology course for 2 years, offering me the opportunity and challenge to teach research methodology in a case-based discussion format. Additionally, I generally give 2-5 lectures a year for medical students, fellows, or local/national CME meetings.

Mentoring students and other trainees has always been a valuable aspect of my professional life. Since joining the UNC faculty, I have mentored 3 medical students on summer research projects, 4 PhD students, 5 adult GI fellows on the GI Epidemiology T32 training program, and 1 Health Services Research fellow on the T32 training program. As evidence of my commitment to mentoring and mentoring success, all 3 medical students have been awarded T35 grants and have presented their work as abstracts at national meetings, and 3 of my PhD or fellow mentees have been awarded other grants (University Research Council, UNC TraCS, and Broad Foundation). Additionally, as indicated on my CV, I have published approximately 30 research articles, 2 review articles, 1 book chapter, and countless peer-reviewed abstracts with a trainee or junior faculty as first author and myself as senior author.


40

My teaching philosophy relies on identifying and capitalizing upon the learner’s intrinsic motivation, and exploring and building upon their prior experiences, knowledge, and beliefs. Whether clinical teaching, lecturing, or mentoring, this usually involves assisting the learner to identify and refine a question or set of related questions and add to their current knowledge base (through discussion, independent study or scientific research). As with all aspects of my academic career, I strive to continuously improve upon my teaching and mentoring by observing the teaching style of others and working to incorporate successful techniques in my own teaching. Additionally, I routinely solicit and review feedback from my learners, carefully reflect upon this feedback, and implement and test changes in response to this feedback. In doing so, I attempt to utilize the principles of clinical QI in my educational endeavors.

Clinical Care and Quality Improvement

In my clinical practice, I specialize in the diagnosis and management of pediatric and adolescent IBD, along with the range of other gastrointestinal conditions. This currently includes approximately ½ to 1 day each week of outpatient clinic and procedures, and 4 weeks each year of inpatient and consult service. I have enjoyed a growing state and national reputation within this clinical niche, as evidenced by a growing number of 2nd opinion consultations and national referrals for patients relocating to North Carolina (or attending college at one of the area universities).

Since my initial fellowship project describing variation in the care for children with this condition, I have long been interested in quality improvement (QI) work. Upon joining the UNC faculty in 2007, I became the physician QI leader for the UNC pediatric IBD program which includes leading our center’s participation in the national pediatric IBD QI network ImproveCareNow (ICN). I served in this capacity until 2016, when the QI leadership of the pediatric IBD program was transitioned to Dr. Ajay Gulati.

Because of my disease knowledge and health services research experience, I have served as Director of Data Management for the network and Chair of the network’s Research Committee. I am currently a member of the network’s Strategy Council and Physician Leadership Committee. Additional work related to IBD quality improvement includes 1) serving on the AGA task force to develop pay-for-performance measures for IBD, serving on the CCFA working group to develop IBD Quality Indicators, and more recently, co-chairing a joint NASPGHAN-AGA task force to develop pediatric IBD performance measures.

In addition to my clinical referrals and the above mentioned service and leadership roles, additional evidence of my national reputation for IBD clinical care and QI include 1) authorship of a number of clinically review articles and book chapters, 2) serving on, co-chairing, or chairing a number of clinically oriented national committees through NASPGHAN and the CCFA, and 3) several invited lectures at local and national meetings.

In the future, I plan to further develop my clinical niche in the diagnosis and treatment of childhood onset IBD, serving the state and regional community by providing skilled and


41

compassionate care to my own patients and by providing second opinions for complex referrals. I will continue my leadership role as the physician leader for our pediatric IBD quality improvement team and hope to expand my leadership role by developing a multidisciplinary pediatric IBD center which will be only center of its kind in the Carolinas.

Professional Service, Leadership, and Patient Advocacy

I am grateful for the many career development opportunities that I have had, both institutionally at UNC and nationally, and I am committed to “giving back” through professional service. I have been on the UNC Department of Pediatrics Strategic Planning Committee and continue to serve on the Faculty Development Committee. In addition to the national committee and leadership roles described above, I have served and will continue to serve on a number of local and national committees to promote science, education, and patient advocacy. This includes currently serving as Chair of the Pediatric Affairs Committee of the Crohn’s and Colitis Foundation of America (CCFA), previously serving as co-Chair the CCFA Professional Education Committee, and serving on both the CCFA National Scientific Advisory Council and the local CCFA Raleigh Area Missions Committee and Triangle Leadership Committee. I was a volunteer physician for the CCFA week-long summer camp program, Camp Oasis, for 6 summers, and have served on the national Camp Oasis Task Force. Additionally, I serve on the Quality Measures Working Group for the American Gastroenterological Association, and have previously served on NASPGHAN IBD committee.

In the future, I hope to continue my professional service and gradually assume greater leadership roles.

Documents

CURRICULUM VITAE Education - findadoc.unchealthcare.org · Cabrera J, Otley A, Rick J, Bousvaros A, Rosh J, Grossman A, Saeed S, Kay M, Carvalho R, Keljo D, Pfefferkorn M, Faubion